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ABSTRACT 
 
Previous results from our group demonstrate that human herpesvirus 8 (HHV-8) triggers 
proangiogenic behavior in endothelial cells by promoting transcriptional activation and secretion of 
monocyte chemoattractant protein 1 (MCP-1), through activation of Nuclear Factor κB (NF-κB). 
However, inhibition of NF-κB still results in partial MCP-1 induction and consequent capillary-like 
structure formation, suggesting the involvement of another transcriptional pathway. Here we 
describe that HHV-8 infection upregulates cellular activating transcription factor 4 (ATF4), a 
member of the CREB family involved in the cell response to ER stress. Upregulation of ATF4 
promotes HHV-8 infection, whereas its silencing decreases virus replication, transcription and 
antigen expression. Furthermore, ATF4 silencing decreases virus-induced MCP-1 production, as 
well as viral induction of tube-like structures in endothelial cells. We also show that ATF4 per se 
activates the MCP-1 promoter and induces proangiogenic properties in transfected endothelial cells. 
The elucidation of molecular mechanism involved in this process will result in a better 
understanding of the angiogenic process, its involvement in cancer and will help in designing novel 
therapies to reduce growth and vascularisation of Kaposi’s sarcoma. 
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RIASSUNTO 
 
Risultati precedentemente ottenuti nel nostro gruppo hanno dimostrato che l’herpesvirus umano di 
tipo 8 (HHV-8) induce proprietà proangiogeniche nelle cellule endoteliali mediante l’induzione di 
MCP-1 (proteina chemiotattica monocitica) in seguito all’attivazione di NF-kB (fattore nucleare 
kB). 
Tuttavia, mutazioni o delezioni dei siti di legame per NF-kB localizzati nella regione promotrice di 
MCP-1, risultano in una parziale inibizione di MCP-1, virus indotto, e nello sviluppo 
dell’angiogenesi, suggerendo l’implicazione di altre vie trascrizionali.  
In questo lavoro è stato analizzato il fattore di attivazione trascrizionale ATF4, dal suo ruolo 
centrale nella risposta cellulare dovuta allo stress, fino alla sua implicazione nell’angiogenesi. 
I risultati mostrano che HHV-8 aumenta l’espressione di ATF4, il quale a sua volta promuove 
l’infezione da HHV-8. ATF4 induce, inoltre, la produzione di MCP-1 e proprietà proangiogeniche 
nelle cellule endoteliali. 
Il silenziamento di ATF4, al contrario, diminuisce la replicazione virale e inibisce la produzione di 
MCP-1 indotta dal virus e quindi l’induzione di strutture tubulari tipiche dell’angiogenesi. 
Si può dunque evincere che ATF4 gioca un ruolo importante nella replicazione di HHV-8 e 
nell’angiogenesi indotta dal virus. 
La comprensione dei meccanismi molecolari implicati in questo processo, potranno contribuire a 
chiarire i processi angiogenici indotti dal virus e potranno pertanto essere utili nel disegno di nuove 
terapie per ridurre lo sviluppo dei tumori virus associati. 
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INTRODUCTION 
 
1. Herpesviruses: general features 
 
1.1.Herpesviruses classification 
 
More than 100 herpesviruses have been discovered, all of them are double-stranded DNA viruses 
that can establish latent infections in their respective hosts. Eight herpesviruses infect humans. 
The Herpesviridae family is subdivided into three subfamilies: the Alpha-, Beta-, or 
Gammaherpesvirinae
1 
(Fig.1). 
 
 
 
 
Figure 1.  Herpesviruses subfamilies. 
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Alphaherpesvirinae are defined by a wide cellular host range, short viral reproductive cycle, 
rapid growth in culture, high cytotoxic effects, and the ability to establish latency in sensory 
ganglia. Human alpha-herpesviruses includes herpes simplex viruses 1 and 2 (HSV-1 and HSV-
2) and varicella zoster virus (VZV), respectively officially designated human herpesviruses 1, 2, 
and 3. 
Betaherpesvirinae have a more restricted host range with a longer reproductive viral cycle and 
slower growth in culture. Infected cells show cytomegalia (enlargement of the infected cell). 
Latency is established in secretory glands, lymphoreticular cells, and in other tissues, such as the 
kidneys and others. In humans, the group includes human cytomegalovirus (HCMV or 
herpesvirus 5) and roseoloviruses (causing the disease roseola infantum in children) including 
human herpesviruses 6A and 6B (HHV-6A and -6B) and human herpesvirus 7 (HHV-7). 
Gammaherpesvirinae in vitro replication occurs in lymphoblastoid cells, but lytic infections may 
occur in epithelial and fibroblasts for some viral species in this subfamily. Gammaherpesviruses 
are specific for either B or T cells with latent virus found in lymphoid tissues (Table 1). Only 
two human gammaherpesviruses are known, human herpesvirus 4, or Epstein-Barr virus (EBV), 
and human herpesvirus 8, referred to as HHV-8 or Kaposi's sarcoma-associated herpesvirus 
(KSHV). The gammaherpesviruses subfamily contains two genera that include both the gamma-
1 or Lymphocryptovirus (LCV) and the gamma-2 or Rhadinovirus (RDV) virus genera. EBV is 
the only Lymphocryptovirus and HHV-8 is the only Rhadinovirus discovered in humans. LCV 
are found only in primates but RDV can be found in both primates and subprimate mammals. 
RDV DNAs are more diverse across species and are found in a broader range of mammalian 
species. 
HHV-8 has sequence homology and genetic structure similar to another RDV, Herpesvirus 
saimiri (HVS). The T-lymphotropic Herpesvirus saimiri establishes specific replicative and 
persistent infection in different primate host species, causes fulminant T-cell lymphoma in its 
primate host and can immortalize infected T-cells. 
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Table 1.  Properties of herpesviruses. 
 
 
1.2.Herpesviruses structure 
 
Herpesviruses have a central toroidal-shaped viral core containing a linear double stranded DNA. 
This DNA is embedded in a proteinaceous spindle
2
. The capsid is icosadeltahedral (16 surfaces) 
with 2-fold symmetry and a diameter of 100-120 nm that is partially dependent upon the 
thickness of the tegument. The capsid has 162 capsomeres.  
The herpesvirus tegument, an amorphorous proteinaceous material that under EM lacks 
distinctive features, is found between the capsid and the envelope; it can have asymmetric 
distribution. Thickness of the tegument is variable depending on the location in the cell and 
varies among different herpesviruses
3
. 
The herpesvirus envelope contains viral glycoprotein protrusions on the surface of the virus. As 
shown by EM there is a lipid trilaminar structure derived from the cellular membranes. 
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Glycoproteins protrude from the envelope and are more numerous and shorter than those found 
on other viruses (Fig.2).  
 
 
 
Figure 2.  Representation of a herpesvirus virion. 
 
 
1.3. Herpesviruses genome 
 
Herpesviruses genomes studied to date range in size from 130 to 235 kbp. 
Herpesviruses DNA is characterized by two unique components, unique long (UL) and unique 
small (US) regions, each flanked by identical inverted repeat sequences. Herpesviruses genome 
also contains multiple repeated sequences. 
All known herpesviruses have capsid packaging signals at their termini
4
. The majority of  genes 
contain upstream promoter and regulatory sequences, an initiation site followed by a 5' 
nontranslated leader sequence, the open reading frame (ORF) itself, some 3' nontranslated 
sequences, and finally, a polyadenylation signal. Gene overlaps are common, whereby the 
promoter sequences of antisense strand (3') genes are located in the coding region of sense strand 
(5') genes; ORFs can be antisense to one another (Fig.3).  
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Figure 3. Genomic organization of some herpesviruses. HSV, VZV and CMV have inverted repeated sequences. 
 
 
Proteins can be embedded within larger coding sequences and yet have different functions. Most 
genes are not spliced and therefore are without introns and sequences for noncoding RNAs are 
present. 
Herpesviruses code for genes that synthetize proteins involved in establishment of latency, 
production of DNA, and structural proteins for viral replication, nucleic acid packaging, viral 
entry, capsid envelopment, for blocking or modifying host immune defences, and for transition 
from latency to lytic growth. Although all herpesviruses establish latency, some (e.g., HSV) do 
not necessarily require latent protein expression to remain latent, unlike others (e.g., EBV and 
HHV-8).  
 
 
1.4.Herpesviruses replication 
 
Herpesviruses can establish lytic or latent infection. 
The lytic stage is divided in different phases: 
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1. Binding to the cell surface. As many other viruses, cell tropism is determined by the 
availability of the correct receptor on the surface of the cell. Binding occurs between the 
herpesvirus envelope glycoproteins and cell receptors. 
2. Envelope fusion with the plasma membrane, mediated by surface virus glycoproteins. 
3. Uncoating: degradation of the tegument in the cytoplasm is followed by transport of the 
nuclear membrane, where virus DNA is introduced in the cell nucleus through pores of 
the nuclear membrane.  
4. Transcription. This is a very complex process, as expected considering the large size of 
viral genome. Viral DNA replicates by circularization followed by production of 
concatemers and cleavage of unit-length genome during packaging. The herpesvirus lytic 
replicative phase can be divided into four stages (Fig. 4): 
 α or immediate early (IE), requiring no prior viral protein synthesis. The genes expressed 
in this stage are involved in transactivating transcription from other viral genes. 
 β or early genes (E), whose expression is independent of viral DNA synthesis. 
 Following the E phase, γ1 or partial late genes are expressed in concert with the 
beginning of viral DNA synthesis. 
 γ2 or late genes (L), where protein expression is totally dependent upon synthesis of viral 
DNA and expression of structural genes encoding for capsid proteins and envelope 
glycoproteins occurs. 
 
 
Fig. 4. Representation of lytic phase of herpesviruses. 
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Herpesvirus DNA is transcribed to RNA by cellular RNA polymerase I. The neo-formed viral 
mRNAs block cellular protein synthesis and activate the replication of viral DNA. Herpesviruses 
encode their own DNA-dependent DNA polymerase and other enzymes and proteins necessary 
to replication, such as ori-Lyt (replication start for the lytic phase), major DNA binding protein 
(MDBP) and origin DNA binding protein (OBP). Herpesviruses can alter their environment by 
affecting host cell protein synthesis and host cell DNA replication, immortalizing the host cell, 
and altering the host's immune responses (e.g., blocking apoptosis, cell surface MHC I 
expression, modulation of the interferon pathway).  
5. Assembly: capsids are assembled in the nucleus. 
6. Maturation and egress: the viral particles bud through the inner lamella of the nuclear 
membrane which has been modified by the insertion of viral glycoproteins and leave the 
cell via the exocytosis pathway (Fig.5).  
 
 
 
 
Figure 5.  Herpesviruses replication cycle. 
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In the latent phase, the virus genome depends on the host replication machinery and replicates as 
closed circular episome. Latency typically involves the expression of only a few latency specific 
genes. Generally, most infected host cells harbour latent virus, as in the case of HHV-8: when 
KS tissue or HHV-8 infected cultured cells are analyzed, the virus is latent in majority of 
infected cells. Different signals such as inflammation and immunosuppression may cause the 
virus to enter into a new lytic phase. 
 
 
2. Human herpesvirus 8 (HHV-8) 
 
Human herpesvirus 8 (HHV-8), also known as Kaposi’s sarcoma associated herpesvirus 
(KSHV), is a member of the Rhadinovirus genus in the gamma-herpesvirus subfamily, first 
detected in 1994 in a patient affected by Kaposi sarcoma (KS)
5
, a neoplasm of endothelial origin. 
Since then, HHV-8 has been identified as the etiologic agent of all epidemiologic forms of KS, 
including classical, endemic African, iatrogenic and AIDS types. In addition,  HHV-8 has been 
implicated in the pathogenesis of other neoplastic disorders affecting immunocompromised 
hosts: primary effusion lymphoma (PEL, a rare form of B-cell lymphoma)
6
, multicentric 
Castleman disease (MCD, a B-cell lymphoproliferative disease)
7
, other lymphoproliferative 
disorders affecting patients infected with HIV
8
, and neoplastic complications in patients after 
transplantation
9
. 
 
 
2.1.  HHV-8 structure  
 
HHV-8 has the typical morphology of the herpesviruses. 
The envelope contains proteins of cellular origin and virus-specific glycoproteins, such as gB, 
gM, gH and K8.1. 
The tegument is an amorphous asymmetric proteinaceous layer between envelope and capsid and 
contains proteins encoded by ORFs 19, 63, 64, 67, 75. 
Each capsid, 125 nm in diameter, contains 12 pentons and 150 hexons which are interconnected 
by 320 triplexes. These capsomers or structural components are arranged in a icosahedral lattice 
with 20 triangular faces. Each asymmetric unit (one-third of a triangular face) of the capsid 
contains one-fifth of a penton at the vertex (Fig. 6). Several proteins are involved in capsid 
assembling: the major capsid protein (MCP), three capsid proteins encoded by ORF62, ORF26, 
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ORF65 and a protease encoded by ORF17. Hexons and pentons contain 5 or 6 MCPs, and 
triplexes contain ORF62 monomer and ORF26 dimer
10
. 
The core contains the linear double stranded DNA.  
 
 
 
 
 
 
Figure 6. Representation of the three-dimensional structures of  gammaherpesvirus capsids. The capsid maps of  KSHV  
is shown as shaded surfaces colored according to particle radius and viewed along an icosahedral three-fold axis. The 
resolution of the KSHV capsid maps is 24 Å. The right two columns are detailed comparisons of a penton and an  
hexon, which were extracted computationally from  map and shown in their top and side views. 
 
 
 
2.2. HHV-8 genome  
 
In the viral capsid, HHV-8 DNA is linear and double stranded, but upon infection of the host cell 
and release from the viral capsid, it circularizes. Reports of the length of the HHV-8 genome 
have been complicated by its numerous, hard-to-sequence, terminal repeats. Renne et al.
11
 
reported a length of 170 kilobases (Kb) but Moore et al.
12
 suggested a length of 270 Kb after 
analysis with clamped homogeneous electric field (CHEF) gel electrophoresis.  
Base pair composition on average across the HHV-8 genome is 59% G/C; however, this content 
can vary in specific areas across the genome.  
HHV-8 possesses a long unique region (LUR) of approximately 145 Kb, containing all the 
known ORFs (open reading frame), flanked by terminal repeats (TRs) (Fig.7). Varying amounts 
of TR lengths have been observed in the different virus isolates. These repeats are 801 base pairs 
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in length with 85% G/C content, and have packaging and cleavage signals. The LUR is similar to 
HVS and at least 66 ORFs have homology with the HSV genes. New genes are still being 
discovered through transcription experiments with alternative splicing. A "K" prefix denotes no 
genetic homology to any HVS genes (K1–K15).  
 
 
 
 
Figure 7.  HHV-8 genome. The genome consists of a long unique region (145 kb) encoding for over 80 ORFs, 
surrounded by terminal repeats regions. 
 
HHV-8 possesses approximately 26 core genes, shared and highly conserved across the alpha-, 
beta-, and gammaherpesviruses. These genes are in seven basic gene blocks, but the order and 
orientation can differ between subfamilies. These genes include those for gene regulation, 
nucleotide metabolism, DNA replication (polymerase ORF9 and thymidin kinase ORF21), and 
virion maturation and structure (envelope glycoproteins: ORF8, ORF22, ORF38). 
HHV-8 encodes several ORFs homologous to cellular genes (at least 12), not shared by other 
human herpesviruses
13
. These genes seem to have been acquired from human cellular cDNA as 
evidenced by the lack of introns. Some retain host function, or have been modified to be 
constitutively active; an example of this is the viral cyclin-D gene
14
. Cellular homologs related to 
known oncogenes have been identified in HHV-8, including genes encoding viral Bcl-2 
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(ORF16), cyclin D (ORF72), interleukin-6 (K2), G-protein-coupled receptor (ORF74), and 
ribonucleotide reductase (ORF2).  
Other genes have homologues in other members of the RDV genus, such as v-cyclin (ORF72), 
latency-associated-nuclear antigen (LANA, ORF73), viral G-protein coupled receptor (ORF74). 
A number of other genes encoding for capsid protein have been identified, including ORF25, 
ORF26, and ORF65. In addition to virion structural proteins and genes involved in virus 
replication, HHV-8 has genes and regulatory components (e.g. ORFs K3, K4 and K5) that 
interact with the host immune system, presumably to counteract cellular host defenses
15
. 
 
 
2.3. HHV-8 replication cycle  
 
Like other herpesviruses, HHV-8 genome structure and gene expression pattern varies depending 
on the replication state. The lytic phase consists of different steps: 
 
1. Binding to the cell surface (Fig. 8) mediated by glycoproteins B and K8.1, encoded by 
ORF8 and K8.1
16
. HHV-8 can use multiple receptor for infection of target cells, and 
these receptors differ according to the cell type. HHV-8 utilizes the ubiquitous cell 
surface heparan sulphate (HS) proteoglycan to bind several target cells (e.g. B 
lymphocytes). Glycoprotein B also interacts with the host cell surface α3-β1-integrin, a 
heterodimeric receptor containing transmembrane subunits. Another cellular receptor 
used is the dentritic cell specific intracellular adhesion molecule-3 (ICAM-3) for the 
binding to the myeloid dendritic cells and macrophages. Moreover, HHV-8 utilizes the 
transporter protein xCT for entry into cells (but not into the B cells); xCT molecule is a 
part of the membrane glycoprotein CD98 complex.  
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Fig. 8. KSHV binding to the cell surface. 
 
2. Fusion between envelope and plasma membrane (Fig. 9). The binding between cellular 
receptors and HHV-8 glycoproteins leads to induction of the host signal cascades 
critical for maintenance of viral gene expression, such as protein kinase C (PKC), 
phosphatidylinositol 3-kinase (PI3K), and nuclear factor kB (NF-kB). In fact, HHV-8 
reprogrammes the elements of host cell transcriptional machinery that are involved in 
regulating a variety of processes (apoptosis, cell cycle regulation, signalling, 
inflammatory response and angiogenesis).  
 
 
                Fig. 9. Fusion between envelope and plasma membrane. 
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3. Uncoating: tegument degradation by cellular enzymes and viral capsid transfer to the 
nuclear membrane. Viral DNA enters in the nucleus. 
 
4. Transcription: viral genome initiates transcription in the nucleus and regulator genes 
are transcribed by host RNA polymerase. mRNAs are translated in virus-specific 
proteins, able to block cellular synthesis and to start viral replication. Lytic gene 
expression begins with transcription of immediate-early (IE) genes that regulate the 
synthesis of other viral genes. Some of the genes transcribed in this step are: ORF6, 
coding the major DNA binding protein (MDBP), ORFs 9, 56, 59, encoding the DNA 
polymerase and ORFs 40, 41, 44 (helicase/primase complex). Expression of IE genes 
occurs independent of viral replication, and afterwards, early and late genes are 
expressed. The early genes (E) expression is activated by IE genes within 24 hours 
after infection or viral reactivation. Early genes encode proteins involved in viral DNA 
replication, nucleotides metabolism, virus assembly. Some early genes are: K2-5, T1.1, 
ORFs2, 41, 59, 70, 74. Expression of late genes (L) begins after viral DNA replication. 
They encode structural proteins involved in virus assembly, such as glycoproteins B 
and H (ORF8 and ORF22), capsid proteins (ORFs 25, 26), the small viral capsid 
antigen (ORF65). 
 
5. Assembly: transcription of genes coding structural proteins and production of viral 
particle. ORFs26 and 29 proteins are responsible for capsid assembly and viral DNA 
packaging. 
 
6. Maturation and egress: the viral particles bud through the inner lamella of the nuclear 
membrane which has been modified by the insertion of viral glycoproteins and leave 
the cell via exocytosis (Fig. 10). 
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Figure 10. Lytic KSHV lifecycle in BCBL-1 cells. 
 
After initial infection, HHV-8 may establish lifelong latency. Throughout latency, viral gene 
expression is tightly regulated and only a few viral genes are expressed. The latent HHV-8 
genome is circularized by joining of GC rich terminal repeats (TRs) at the ends of the viral 
genome to form an extrachromosomal circular episome
17
. The latency associated nuclear antigen 
(LANA) regulates episome replication by host cell machinery
18
. LANA is a phosphoprotein 
expressed in latently infected cells and promotes the maintenance of latency by associating with 
the ORF50 promoter
19
 or binding cellular factors which normally interact with ORF50. HHV-8 
infection can be reactivated from latency and the lytic gene expression may restart. 
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2.4. HHV-8 transactivator genes  
 
Two immediate-early genes play a key role in the reactivation from latent phase to lytic phase: 
ORF50 and ORF57. 
 ORF50 
ORF50 is an immediate early gene whose product is the major transcriptional transactivator and 
his activity is required for viral reactivation by all known chemical inducer (e.g. tetradecanoyl 
phorbol acetate, TPA). The ORF50 gene is rapidly expressed, within 2 to 4 h after induction. 
ORF50 belongs to the family of R transactivators, highly conserved among herpesviruses and is 
related to immediate-early transcriptional activator proteins of other gammaherpesviruses, such 
as ORF50a encoded by Herpesvirus saimiri and Rta encoded by the BRLF1 ORF of Epstein-
Barr virus
20
.  
During latency, ORF50 expression is repressed; however, ORF50 may be activated by 
physiological conditions, such as hypoxia, or by pharmaceutical agents and the activation 
triggers the start of the lytic replication cascade. 
The genomic sequence of ORF50 is characterized by 5 exons and 4 introns (Fig.11) and 
transcribes an mRNA of 3,6 Kb. The transcript initiates at position 71560, 23 nts downstream a 
potential TATA box; its first AUG is located at position 71596. 
 
 
 
 
 
Figure 11.  Schematic representation of ORF50 protein. 
 
 
The ORF50 transcript encodes a 691 aa protein (110 kDa) located in the nucleus during the 
latent phase for the presence of two nuclear localization signals (NLSs). The N-terminus 272 
amino acids of ORF50 binds independently to HHV-8 promoters and mediates sequence-specific 
DNA binding; N-terminal region is followed by a leucine zipper domain. The C-terminal domain 
contains multiple charged amino acids alternated with repeated bulky hydrophobic residues, a 
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primary structure conserved in many eukaryotic transcriptional activation domains. The C-
terminus is sufficient to activate transcription when targeted to promoters with a heterologous 
DNA binding domain
21
. 
This region contains four overlapping domains termed activation domains (AD1, AD2, AD3, 
AD4), sharing significant homology to the R proteins encoded by other gamma-herpesviruses. 
Analysis of the ORF50 amino acids sequence reveals multiple sites of phosphorilation, including 
a C-terminal region rich in serines and threonines, and 20 other consensus sites for 
phosphorilation by serine-threonine kinase and protein kinase C (PKC). 
R response elements (RREs) have been identified within several lytic gene promoters. The 
response element contains a 12-bp palindrome with additional sequences flanking the 
palindrome which are also required for both DNA binding and activation by ORF50. 
The ORF50 protein binds directly to this palindromic sequence, and the N-terminal 272 aa is 
sufficient for binding in vitro. ORF50 can directly transactivate the early gene promoters
22
.  
The ORF50-responsive promoters include the following: ORF 6 (single-stranded DNA binding 
protein), ORF21 (thymidine kinase [TK]), ORF57 (posttranscriptional activator), ORF59 (DNA 
polymerase associated processivity factor), K8 (K-bZip), K9 (viral interferon response factor), 
K12 (kaposin), and nut-1 or PAN or T1.1 (polyadenylated nuclear RNA)
23
. 
Furthermore, recent studies suggest autoactivation of ORF50 by interaction with the cellular 
protein octamer-1 (oct-1) and an intact octamer element that is located approximately 200 bp 
upstream of the ORF50 transcription start site
24
. 
Expression of ORF50 reactivates viral lytic cycle in cells containing the virus in a latent phase
25
, 
and is also able to activate heterologous viral promoters such as LTR HIV, synergizing with 
Tat
26
. This molecular transactivation increases cellular susceptibility to HIV infection and could 
have clinical consequences in patients co-infected with HHV-8 and HIV. 
The constitutive expression of ORF50 in stable clones increases expression of several cellular 
transcription factors, including activating transcriptional factor-4 (ATF4) (Unpublished data). 
 ORF57  
ORF57 is a lytic gene expressed between 2 and 4 h after activation of the lytic phase, 
immediately following the appearance of ORF50 transcripts but prior to most early mRNAs.  
ORF57 is homologous to known posttranscriptional regulators in other herpesviruses. One of 
these, ICP27 of HSV is a regulator whose functions include downregulation of intron containing 
transcripts and upregulation of some late messages. ICP27 is essential for lytic viral replication, 
is required for inhibition of host cell splicing and shuttles from the nucleus to the cytoplasm to 
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promote the export of intronless viral RNAs
27
. The other gammaherpesviruses, EBV and 
herpesvirus saimiri, also encode ICP27 homologs. 
ORF57 gene is positioned in a unique long region of the HHV-8 genome and is flanked by 
ORF56 (primase) and K9 (viral interferon regulatory factor, vIRF) genes. ORF56 and ORF57 
have their own promoter to initiate transcription, but they share the same polyadenilation signal 
downstream of ORF57.                       
ORF57 contains two coding exons and a single 108 bp intron (Fig.12). The exon 1 is relatively 
small, 114 nts, and has four ATG codons, clustered within a region of 33 nucleotides, in frame 
with each other and with the first exon and separated from it by a single stop codon. The intron is 
109 nts in size and contains consensus splice donor and acceptor sites. The exon 2 is about 1,4 
kb long. The transcriptional start site (TSS) is located at nt 82003 and polyA signal starts at nt 
83608. A TATA box 24 bp is identified upstream the TSS as well as several consensus 
transcription factor binding sites (NF-kB, AP-1, Oct-1), and at least four R responsive elements 
involved in the transcriptional activation by ORF50. 
 
 
 
 
 
 
Figure 12.  Schematic representation of ORF57 mRNA. 
 
 
ORF57 expression is highly dependent on ORF50, and a RRE in the ORF57 promoter is 
responsible for ORF57 binding.  
ORF57 is expressed predominantly in the nucleus and nuclear localization is driven by three 
independent nuclear localization signals (NLS) that form a cluster in the N-terminal.  
ORF57 encodes a protein of 455 aa residues. 
Analyses of amino acid sequence reveals several structural and functional motifs. The N-
terminus contains a long stretch of arginine residues, two separate RGG-motifs, which are 
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typical of RNA-binding proteins and four serine/arginine dipeptides, characteristic of SR 
proteins, the major cellular splicing factors. The three NLSs overlap the arginine rich region. 
The C terminus of ORF57 is enriched in leucine residues and contains a leucine zipper motif, 
typical of cellular transcriprion factors. The C-terminus also contains the zinc-finger-like motif. 
ORF57 promotes the expression of HHV-8 intronless genes, including several viral early and 
late genes, such as ORF59, T1.1 (PAN or nut-1), gB, MPC. ORF59 is an early gene encoding a 
viral DNA polymerase processivity factor involved in viral DNA replication. T1.1 is a non-
coding RNA that accumulates at unusually high levels in the nucleus of lytically infected cells. 
ORF50 and ORF57 have a synergic activity that is promoter specific: expression of some 
promoters that are upregulated by ORF50 can be synergistically enhanced by coexpression with 
ORF57. This synergy results from a post-translational enhancement of the transcriptional activity 
of ORF50. ORF57 transactivates specific viral promoters in synergy with ORF50, such as 
promoters of T1.1, ori-Lyt and Kaposin. ORF57 interacts with ORF50 via its N-terminal region 
and the central region of ORF50. 
 
 
2.5. HHV-8 epidemiology and transmission  
 
The serologic prevalence of HHV-8 infection has been explored in most continents worldwide 
and in different populations with different levels of risk of HHV-8 infection. It should be noted 
that the comparisons of prevalence are limited by the fact that either antibodies to latent or lytic 
HHV-8 antigens were detected. Several studies have confirmed that there is a low 
seroprevalence in central and northern Europe, North America and most of Asia, intermediate 
prevalence in the Middle East and Mediterranean, and high prevalence in southern Africa 
(Fig.13). 
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Fig. 13.  KSHV seroprevalence rates. 
 
 
The virus, first thought to be transmitted only sexually, is now also considered transmissible 
through low risk or more casual behaviours. Important risk factors for transmission of the virus 
are a spouse's seropositivity and maternal seropositivity. Of all anatomic sites, HHV-8 DNA is 
found most frequently in saliva, which also has higher viral concentrations than other 
secretions
28
. For this reason, it has been hypothesized that saliva could be the route of casual 
transfer of infectious virus among family members.  
Other possible transmissions are blood-borne and organ transplantation. 
 
 
2.6. HHV-8 pathogenesis 
 
Human herpesvirus 8 is associated with proliferative disorders including Kaposi’s sarcoma (KS), 
multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and other 
lymphoadenopathologies (Fig. 14). 
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Fig. 14. Representation of proliferative disorders associated to KSHV. 
   
 
HHV-8 induces the formation of neoplasias in natural or experimental hosts, and reactivation 
from latency is essential for this activity. 
Latent viral proteins, such as vFLIP and LANA, inactivate tumour suppressors and block 
apoptosis
29
.  
However, lytic replication is also important for transmission of the virus in the population and in 
the pathogenesis of KS. HHV-8 vIL-6 is highly expressed during the lytic cycle, and promotes 
cellular growth and angiogenesis, while protecting against apoptosis
30
.  Additional evidence for 
the importance of lytic replication includes the fact that inhibition of active HHV-8 replication 
by gancyclovir reduces the incidence of HHV-8 in HIV-infected individuals
31
.                  
 
 Kaposi’s sarcoma 
KS was first described by Moritz Kaposi in the 1870s
32
 and was described as an aggressive 
tumour affecting patients younger than those currently observed. For all epidemiological forms 
of KS, the tumour presents as an highly vascularised neoplasm that can be polyclonal, 
oligoclonal, or monoclonal. Its antigenic profile suggests either endothelial, lymphoendothelial, 
or macrophage origins. All forms of KS lesions contain a variety of cell types, including 
endothelium, extravasated erythrocytes, infiltrating inflammatory cells, and characteristic 
“spindle” cells of endothelial origin33 (Fig.15). The spindle cells express both endothelial and 
macrophagic markers.  
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Fig. 15. Cellular transformation in Kaposi’s sarcoma. 
 
 
Extensive and aberrant neoangiogenesis in KS lesions is accompanied by elevated levels of 
many cytokines, including basic fibroblast growth factor (bFGF), interleukin-1 (IL-1), IL-6, IL-
8, platelet-derived growth factor (PDGF), tumour necrosis factor (TNF), gamma interferon (IFN-
), and vascular endothelial growth factor (VEGF). Many of these cytokines are secreted by 
spindle cells, are essential for spindle cell viability in culture, and are themselves proangiogenic 
(Fig. 16).  
HIV infection increases the risk for development of KS, and therefore, the incidence of KS has 
increased substantially during the HIV pandemic, particularly in younger HIV-infected 
patients
34
. 
 
 
 
Microscopic cellular transformation in Kaposi’s sarcoma 
Macroscopic cellular transformation in Kaposi’s sarcoma 
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Figure 16. Representation of Kaposi’s sarcomagenesis. 
 
 
Four forms of Kaposi’s sarcoma are known, differentiated on clinical parameters and 
epidemiology:  
Classic KS: is an indolent tumour affecting the elderly population, preferentially men, in 
Mediterranean countries. The lesions tend to be found in the lower extremities and the disease, 
due to its non-aggressive course, usually does not kill those afflicted.  
AIDS-KS: in the context of the acquired immunodeficiency syndrome (AIDS), KS is the most 
common malignancy and is an AIDS defining illness
35
. AIDS-KS is a more aggressive tumour 
than classic KS and can disseminate into the viscera with a greater likelihood of death. It 
presents more often multifocally and more frequently on the upper body and head regions. 
Endemic KS: HHV-8 was prevalent in Africa prior to the HIV epidemic. Prior to HIV 
coinfections, endemic KS affected men with an average age of 35 and very young children
36
. 
HIV coinfection has raised the prevalence of KS significantly in Africa, where endemic KS is 
found more often in women and children than in other areas of the world
37
.  
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Iatrogenic KS: Immunosuppression, as that occurring in transplant recipients, is known to 
facilitate reactivation of herpesviruses and therefore transplant patients under 
immunosuppressive therapy can develop KS. Withdrawal of the therapy can cause the KS to 
regress
38
.  
 
 Multicentric Castleman disease 
MCD is a rare polyclonal B-cell angiolymphoproliferative disorder. Most of the B-cells in the 
tumour are not infected with HHV-8, and the HHV-8 infected cells are primarily located in the 
mantel zone of the lymphatic follicle. It is thought that uninfected cells are recruited into the 
tumour through HHV-8 paracrine mechanisms, such as vIL-6, a known growth factor for the 
tumour. More than 90% of AIDS patients with MCD are HHV-8 positive, whereas MCD in the 
context of no HIV infection has a HHV-8 prevalence of approximately 40%
39
.  
 
 Primary effusion lymphoma 
First identified as a subset of body-cavity-based lymphomas (BCBL), PELs contain HHV-8 
DNA sequences
6
. These lymphomas are distinct from malignancies that cause other body cavity 
effusions. PEL cell lines have 50–150 copies of HHV-8 episomes per cell40. 
 
 
2.7. HHV-8 and angiogenesis 
 
The effects of acute HHV-8 infection on endothelial cell functions, induction of angiogenesis, 
and triggering of inflammatory processes are still largely unknown. 
In our laboratory, we demonstrated that HHV-8 selectively triggers the expression and secretion 
of high levels of monocyte chemoattractant protein 1 (MCP-1). We also found that this event is 
accompanied by virus-induced capillary-like structure formation at a very early stage of acute 
infection
41 
(Fig.17). 
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            Figure 17.  HUVEC monolayer not infected or infected with HHV-8 
41
. 
 
 
The MCP-1 expression is controlled by the nuclear factor kB (NF-kB), that induces the 
expression of chemokines promoting cell migration and angiogenesis, such as IL-8 and vascular 
endothelial growth factor (VEGF), several matrix metalloproteinases (MMPs) that promote 
tumour invasion of surrounding tissue. NF-kB is a critical regulator of the immediate early 
response to HHV-8, playing an important role in promoting inflammation, in the control of cell 
proliferation and survival, and in the regulation of virus replication. Several studies show that 
transfection of different HHV-8 genes results in NF-kB activation in different cell types, and in 
our laboratory we demonstrated that HHV-8 acute infection induces NF-kB activation in 
endothelial cells. The human MCP-1 gene contains 2 NF-kB-binding sites in the enhancer 
region. The kB binding sites are required for TPA-induced expression. In HHV-8 infection we 
observed that the NF-kB pathway is involved in the enhancement of MCP-1 expression and is 
required for maximal production of the chemokine. However, mutations in both NF-kB sites in 
the enhancer region did not result in the complete loss of promoter induction in HHV-8 infected 
cells, and inhibitors of NF-kB do not prevent MCP-1 activation following HHV-8 infection 
suggesting that at least another signalling pathway may be involved in the control of MCP-1 
expression in the course of acute HHV-8 infection. 
 
 
 
 
 
Pag. 29 
 
  
3. The cellular activating transcription factor 4 (ATF4) 
 
ATF4 (also called cAMP responsive element binding 2, CREB2) belongs to the ATF/CREB 
family of transcription factors that represent a large group of basic region-leucine zipper (bZip) 
proteins. The basic region of the bZIP protein interacts with DNA, and they dimerize by their 
leucine zipper domains forming homodimers, heterodimers or both
42
 (Fig. 18). 
CREB/ATF family members include ATF1 (also known as TREB36), CREB/CREM, CREB314 
(also known as Aibzip or Atce1), CREB-H, ATF2 (also known as CRE-BP1), ATF3, ATF4, 
ATF6, ATF7, B-ATF and ATFX (also known as ATF5). 
ATF4 gene is in chromosome 22 at the cytogenetic band 22q13.1, located at 38,241,069–
38,243,191 bp, with a genomic size of 2122 and is constitutively expressed in many cells. 
The structure of human ATF4 mRNA includes three short open reading frames (uORFs) in the 
5’UTR that precede the functional coding sequence43 and are out of frame with the main protein-
coding region. The organization of the 5’UTR uORFs in ATF4 is essential for the response of 
ATF4 to stress such as ER stress and hypoxia. 
ATF4 protein consists of 351 amino acids. The protein is structured into several domains/motifs 
that are essential for ATF4 homo/heterodimerization and DNA binding. A transcriptional 
activation domain has been located at the N-terminus of ATF4
44
. 
 
 
 
Figure 18. Representation of Leucine Zipper bound to DNA. 
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The mammalian ATF4 can form a homodimer, and heterodimers with members of the AP-1 and 
C/EBP family of proteins, including Fos and Jun
45
, and several C/EBP proteins
46
. ATF4 has a 
very short half-life of about 30-60 minutes. 
ATF4 has several interacting partners, which include p300
47
, RNA polymerase II subunit 
RPB3
48
, ZIP kinase, a serine/threonine kinase, which mediates apoptosis
49
, HTLV1 
transactivator Tax, which activates the expression of viral mRNA through a three 21 bp repeat 
enhancer located within the HTLV-1 LTR
50
. Tax transactivates the HTLV-1 promoter via the 
Tax responsive elements that contain the consensus ATF/CRE core sequence. ATF4 enhances 
the ability of Tax to transactivate the HTLV-1 promoter. The numerous dimerization and 
interaction partners determine the diverse functions of ATF4. 
ATF4 can function as a transcriptional activator, as well as a repressor. It is a stress responsive 
gene, which is upregulated by several factors/stressors, including oxygen deprivation 
(hypoxia/anoxia), amino acid deprivation, endoplasmic reticulum stress (ER stress), oxidative 
stress, and by the growth factor heregulin
51
. 
In mammalian cells, hypoxia/anoxia and perturbation of ER homeostasis induces a complex 
transcriptional program and triggers a reduction in protein translation (UPR: unfolded protein 
response). A central mediator of this translational response to anoxia is phosphorylation of the 
eukaryotic initiation factor 2 (eIF2) by PERK protein kinase. Although the phosphorylation of 
eIF2 results in global translational reduction, it specifically increases the translation of ATF4 
mRNA. The various stress signals integrate in a common pathway of increased translation of 
ATF4, which subsequently ensures supply of amino acids for protein biosynthesis and protects 
cells against oxidative stress, by modulating a number of genes involved in mitochondrial 
function (e.g., Lon mitochondrial protease homologue), amino acid metabolism and transport 
(e.g., asparagine synthetase), as well as in redox chemistry (e.g., NADH cytochrome B5 
reductase homolog). As a result of metabolic and ER stress that activate the PERK pathway of 
translational inhibition, ATF4 initiates a feedback regulatory loop to ensure the transient nature 
of protein synthesis inhibition. ATF4 induces GADD34 transcription, a component of the 
phosphatase complex that dephosphorylates eIF-2alpha. 
Some of the genes that are induced by ATF4 include receptor activator of nuclear factor-kappa B 
(RANK) ligand (RANKL), osteocalcin, E-selectin, VEGF, Gadd153, gadd34, asparagine-
synthesase, TRB3, and several genes involved in mitochondrial function, amino acid metabolism 
and redox chemistry
52 
(Fig. 19).  
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Figure 19. Several events cause cellular stress. The ER protein kinase (PERK) is activated by homodimerization 
and autophosphorylation to phosphorylate eIF2α, thereby reducing the rate of mRNA translation and the 
biosynthetic protein-folding load on the ER. eIF2α phosphorylation paradoxically increases translation of ATF4 
mRNA to produce a transcription factor that activates expression of genes encoding protein chaperones, ERAD 
machinery, enzymes that reduce oxidative stress, and functions in amino acid biosynthesis and transport. 
 
 
 
One important stress factor relevant to cancer progression is hypoxia and more extremely, 
anoxia. Tumour hypoxia/anoxia is associated with a more aggressive clinical phenotype, and 
ATF4 protein has been observed to be in much greater levels in primary human tumours 
compared to normal tissues
53
. 
ATF4 induces VEGF and E-selectin which may be associated with increased metastasis. Since 
ATF4 protein has shown to be present at greater levels in cancer compared to normal tissue, and 
it is upregulated by signals of the tumour microenvironment such as hypoxia/anoxia, oxidative 
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stress, and ER stress, it could potentially serve as a specific target in cancer therapy. As a target 
ATF4 is attractive because it is also potentially involved in angiogenesis and adaptation of 
cancer cells to hypoxia/anoxia, which are major problems in cancer progression. The induction 
of VEGF (vascular endothelial growth factor) has a key role in angiogenesis, and preliminary 
study in our laboratory demonstrate that transfection of ATF4 induces capillary-like structure 
formation in vitro. 
Many viruses have been shown to induce ER stress and activate the UPR: these include three 
members of the flavivirus, C hepatitis and HCMV. Viral infection induces the cell response to 
stress, which should lead to an attenuation of viral replication. However, some aspects of the 
UPR can be regulated and limited by the virus. For example, infection with HCMV 
(betaherpesvirus) induces the UPR by regulating specifically three signalling pathways: PERK, 
ATF6 (activating transcription factor 6) and Ire-1
54
.  
Cells infected with this betaherpesvirus show an increase in ATF4 protein levels, leading to the 
activation of genes involved in metabolism and redox reactions and helping the virus to maintain 
a cellular environment permissive to infection. 
Studies demonstrate that also HHV-8 can interact with ATF4. LANA, the latency associated 
nuclear antigen, encoded by ORF73, represses the transcriptional activation activity of ATF4 and 
the interaction requires the bZIP domain of ATF4. Repression by LANA is independent from the 
DNA-binding ability of ATF4
55
. 
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AIM OF THE RESEARCH 
 
Angiogenesis, the formation of new blood vessels, is the hallmark of cancer, and aggressiveness of 
primary tumours depends on the novo angiogenesis. A large number of proangiogenic factors have 
been identified, including well known cytokines with predominant angiogenic activity, such as 
VEGF. 
Activating Transcription Factor 4 is a central factor used by the cell to respond to multiple, 
seemingly divergent stresses, including nutrient depletion, oxidative stress, UV irradiation, 
reductive stress, exposure to toxins, hypoxia. 
The detailed molecular events controlling stress response have not been fully elucidated, but it is 
known that ATF4 is a common downstream target that integrates signalling from different stimuli. 
This pathway is collectively referred to as the Integrated Stress Response (ISR) and consequent 
unfolded protein response (UPR). Several conditions can cause protein misfolding, such as altered 
metabolic conditions including anoxia and hypoxia, expression of mutant proteins and infection by 
viruses, including hepatitis C virus, Japanese encephalitis virus, bovine diarrhoea virus, 
adenoviruses and human Cytomegalovirus. ATF4 is also related to hypoxia tolerance and tumour 
progression, is overexpressed in tumours and it can crosstalk with NFkB in controlling VEGF-
dependent tumour angiogenesis. In particular, ATF4 cooperates with NFkB in activating the 
signalling cascade that ultimately increases VEGF expression, associated to different grades of 
breast cancer. Similarly, in a human medulloblastoma cell line treated with UPR inducers, ATF4 
was shown to bind to VEGF gene, although its contribution to VEGF transcription appeared to be 
fairly modest. In spite of these evidences, a direct role of ATF4 in the induction of proangiogenic 
properties in primary endothelial cells is not yet well defined, and the observations reported so far 
are mainly direct. The recent observation that silencing of ATF4 impairs monocyte chemotactic 
protein 1 (MCP-1) transcription in aortic endothelial cells, is particularly interesting in the context 
of the role of MCP-1 as a potent mediator of the angiogenesis induced by human herpesvirus 8 
infection. 
HHV-8, also known as KS-associated herpesvirus (KSHV), is the causative agent of Kaposi’s 
sarcoma (KS), and has been implicated as a major agent in the development of primary effusion 
lymphomas (PEL), multicentric Castleman’s disease and lymphoproliferative disorders affecting 
HIV-infected patients. Despite the name, KS is not a true sarcoma but a “vascular” neoplasm, 
containing abnormally dense and irregular blood vessels, that fill with blood cells, giving the 
tumour its characteristic bruise-like appearance. Several morphologic variants of KS are known, but 
all the described forms are characterized by angiogenesis and contain tumour cells of endothelial 
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origin with a characteristically abnormal elongated shape, called spindle cells. Inflammatory cells, 
including lymphocytes, plasma cells and dendritic cells, are also present in KS lesions. The majority 
of neoplastic cells in KS support a latent HHV-8 infection and virus lytic replication, required for 
neoplastic development, is limited to a small number of cells. Several HHV-8 gene products, 
including homologues of cellular oncogenes, cytokines, chemokines and chemokine receptors, have 
been related to endothelial growth and transformation.  
We recently reported that HHV-8 activates NFkB in endothelial cells, promotes transcriptional 
activation and secretion of MCP-1, and induces MCP-1-dependent angiogenesis. However mutation 
or deletions involving NFkB binding sites located in the MCP-1 enhances region resulted only in a 
partial inhibition of HHV-8 induced MCP-1 transcription and angiogenesis, suggesting the 
involvement of at least another transcriptional pathway. 
These observations prompted us to investigate the role of ATF4 in inducing neo-angiogenesis in 
primary human endothelial cells, with particular focus on a possible crosstalk with MCP-1 in the 
induction of the proangiogenic phenotype. Our results show that ATF4 has a direct role in 
promoting neo-angiogenesis in endothelial cells. In fact, the overexpression of ATF4 induces 
capillary-like structure formation, and activates directly the enhancer-less promoter of MCP-1, 
inducing the release of MCP-1. 
We investigated also the possible relationship between ATF4 and HHV-8 induced angiogenesis. 
We found that in vitro HHV-8 infection increases ATF4 expression, most likely through the action 
of the major viral transactivator ORF50, and this upregulation is directly associated to virus 
proangiogenic potential, possibly by the induction of MCP-1 production. 
These data provide new insights into the mechanism underlying the regulation of angiogenic 
process, both as a consequence of cellular stress conditions or virus infection, and might help to 
understand the basis of tumour angiogenesis, opening new therapeutic regimens for the 
management of tumours such as Kaposi’s sarcoma. 
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METHODS 
 
1. Cells 
 
For angiogenesis studies human umbilical vein endothelial cells (HUVECs) were used
56
. HUVECs 
were cultured in EGM-2 medium (BioWhittaker, Walkersville, MD), using collagen coated flasks 
(Biocoat Collagene, BD Biosciences, Bedford, MA). All the experiments were performed on third 
to fifth passages HUVECs.  
For the infections and transfection studies the following human cell types were used: HUVECs, 
human microdermal endothelial cells (HMECs), 293 epithelial cell line and Jurkat T cell line. 
HMECs were obtained from derma, immortalized by infection with a replication-defective adeno-
5/SV40 virus as previously described
57
, and cultured in EGM-2 medium. The human 293 cell line 
(ATCC CRL-1573) was grown in complete DMEM medium plus 10% inactivated fetal calf serum  
(FCS). The Jurkat T cell line (ATCC TIB-152) was grown in complete RPMI medium plus 10% 
FCS. The PEL-derived BC-3 cell line
58
, used for HHV-8 production, was maintained in RPMI 
medium (Gibco, Invitrogen, Carlsbad, CA) supplemented with 2 mM L-glutamine, 100 U/ml of 
penicillin, and 100 µg/ml of streptomycin (complete medium) and 20% FCS
41
. 
All cells were cultured at 37°C in the presence of 5% CO2. 
 
 
2. Plasmids 
 
Transfection experiments were performed using recombinant plasmids pCR-50sp, pGL-PR57, pGL-
PR50, pGL-PRT1.1, pGLM-PRM, pGLM-ENH, pGLM-MA1MA2, pRL-SV40 and pCG-ATF4.  
Spliced forms of ORF50 were cloned in the expression vector pCR3.1-Uni (Invitrogen) in our 
laboratory
25
. Briefly, spliced genes were obtained from TPA-activated BCBL-1 cells by specific 
retrotranscription of polyA RNA followed by PCR amplification. Amplified fragments were 
sequenced to verify their integrity and were then inserted into the vector pCR3.1-Uni to obtain the 
recombinant plasmid pCR-50sp. 
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Fig. 19. Schematic representation of  eukaryotic expression vector pCR3.1-Uni, utilized for cloning of genes ORF50 
and ORF57. 
 
 
HHV-8 gene promoters were cloned in the reporter vector pGL3-Basic in this laboratory
56
, 
containing the Firefly luciferase gene cloned under the transcriptional control of HHV-8 promoters.  
The MCP-1 promoter-luciferase constructs (provided by Dr. T. Yoshimura)
57
 contain the proximal 
promoter (pGLM-PRM), the proximal promoter and the distal enhancer (pGLM-ENH), the 
proximal promoter and the distal enhancer in which both NF-kB sites are mutated (pGLM-
MA1MA2). 
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Fig. 20. Schematic representation of  reporter vector pGL3-Basic, utilized for cloning of HHV-8 promoters genes. 
 
 
pRL-SV40 vector (Promega) was used as an internal transcriptional control, and contains the 
Renilla luciferase gene cloned under the transcriptional control of the SV40 virus promoter. 
 
 
 
 
Fig. 21. Schematic representation of  expression vector pRL-SV40, utilized for cloning of Renilla gene. 
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pCG-ATF4 plasmid contains the ATF4 gene cloned under the transcriptional control of the CMV 
promoter, and was a kind gift of Dr. T. Hai
51
. 
 
                   
 
 
Fig. 19. Schematic representation of expression vector pCG-AFT4. 
 
 
 
3.  DNA extraction 
 
Genomic DNA was extracted from 10
6
 cell samples. 
Cells were lysed in 500µL lysis buffer (10 mM Tris-HCl pH 8.0, 10 mM disodium EDTA pH 8.0, 
10 mM NaCl, 0.6% SDS and 100 µg/ml proteinase K) and incubated at 37°C for a minimum time 
of 4 hours. After three cycles of phenol:chloroform:isoamyl alcohol (25:24:1) extractions, DNA 
was recovered by ethanol precipitation, suspended in sterile water, and RNase A was added to a 
final concentration of 100 µg/ml. Following 1 hour incubation at 37°C, RNase A was removed by 
phenol extraction. After precipitation with ethanol, DNA pellets were dissolved in sterile water and 
stored at -20°C until PCR or qPCR analysis. 
DNA concentration was determined by reading optical density at 260 nm. 
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4. RNA extraction and retrotranscription 
 
Total RNA was extracted with RNAzol B (Tel-Test), following the protocol provided by the 
manufacturer. Briefly, 10
6
 cell samples were lysed with RNAzol, then, chloroform in ratio 1:5 was 
added. The mixture was centrifuged 20 minutes at 8500 x g and the aqueous phase was collected 
and RNA precipitated with isopropanol. After two washes with 75% ethanol and DNAse treatment 
(4 U/mg RNA, 3 x 20 min. at room temperature), RNA was precipitated with isopropanol 20 
minutes at 8500 x g at 4°C. RNA quality was checked by electrophoretic analysis on a 0.8% 
agarose gel. The absence of contaminating DNA was checked by PCR amplification of human β-
actin gene before retrotranscription (RT-). Negative PCR results for β-actin ensured that the RNA 
sample was completely free from DNA sequences. First strand cDNA synthesis was carried out 
with MuLV reverse transcriptase and random hexamer primers (Applied Biosystems), following the 
manufacturer’s instructions, retrotranscribing 2 µg of total RNA from all the samples. The mixture 
was incubated for 1 hour at 42°C. Efficiency of retrotranscription was assessed by analysis of 
dilutions of cDNA with PCR specific for human β-actin gene (RT+). 
 
 
5. PCR and rtPCR 
 
The presence and the level of transcription of HHV-8 were analyzed by PCR and reverse 
transcription PCR (rtPCR) amplification of the ORF26 and ORF50 genes. PCR amplification was 
performed using 100 ng total DNA or 200 ng total cDNA extracted from infected cells. 
Amplification of the housekeeping β-actin gene was used as a control. The transcription of ATF4 
was analysed by rtPCR amplification of the ATF4 gene. Specific primers and PCR conditions are 
described in Table 2. The absence of contaminating DNA was checked by PCR amplification of 
human β-actin gene before retrotranscription. Negative PCR results for β-actin ensured that the 
RNA sample was completely free from DNA sequences, and that positive amplification after 
retrotranscription was positively associated to viral transcripts. 
Particular care was taken to avoid sample-to-sample contamination: different rooms and dedicated 
equipment were used for DNA extraction and processing, for PCR set-up and gel analyses, all 
pipette tips had filters for aerosol protection. 
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GENES  PRIMERS  SEQUENCES  AMPLICONS 
ORF50  ORF50-Forw 
ORF50-Rev  
5'-TTGGTGCGCTATGTGGTCTG-3‘ 
5'-GGAAGGTAGACCGGTTGGAA-3'  
420 bps 
ORF26  ORF26-Forw 
ORF26-Rev  
5'-GCCGAAAGGATTCCACCAT-3‘ 
5'-TCCGTGTTGTCTACGTCCAG-3'  
232 bps 
ATF4 ATF4-Forw 
ATF4-Rev 
5’-GTGGCCAAGCACTTCAAACC-3’ 
5’-GGAATGATCTGGAGTGGAGG-3’ 
414 bps 
β-actin  HACT-Forw  
HACT-Rev  
5’-TCACCCACACTGTGCCCATCT-3’ 
5’-GACTACCTCATGAAGATCCTCAC-3’ 
674 bps 
 
 
GENES 
 
CONDITIONS  
 
CYCLES 
 
[Mg
Cl2] 
 
ORF50 
 
94°C  5min 
94°C  30 sec, 57°C  1 min, 72°C  1 min + ext. 3 sec/cycle 
72°C  10 min, 4°C >>> 
 
 
1 
35 
1 
 
 
2mM 
 
ORF26 
 
94°C  5min 
94°C  1min, 57°C  1 min, 72°C  1 min + ext. 3 sec/cycle 
72°C  10 min, 4°C >>> 
 
 
1 
45 
1 
 
 
1.5 
mM 
 
ATF4 
 
94°C  5min 
94°C  1min, 57°C  1 min, 72°C  1 min + ext. 3 sec/cycle 
72°C  10 min, 4°C >>> 
 
1 
35 
1 
 
 
2mM 
 
β-actin 
 
94°C  5min 
94°C  1min, 57°C  1 min, 72°C  1 min + ext. 3 sec/cycle 
72°C  10 min, 4°C >>> 
 
1 
30 
1 
 
 
1.25
mM 
 
Table 2. Primer sets and thermal conditions used for PCR and rtPCR reactions. 
 
 
6. Cell transfections 
 
Jurkat, BC-3 and BCBL-1 cells were seeded 24 hours before transfection to obtain optimal cellular 
density (10
6
 cells/mL) and 10
6
 cell samples were transfected with 1 µg of plasmid DNA by 
nucleofection (Nucleofector, Amaxa), following the manufacturer’s instructions. This method 
permits to obtain high efficiency of transfection, carrying the exogenous DNA into the cells and 
directly into the nucleus. Efficiency of transfection determined in parallel samples by transfection 
with pMax- GFP plasmid (Amaxa).  
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HeLa and 293 cells were seeded in 24-well plates 24 hours prior to transfection to obtain optimal 
confluence, then were transfected with 1µg of plasmid DNA by GeneJuice Transfection Reagent 
(Novagen), based on polyamine formulation, following the manufacturer’s instructions. 
 
 
7. Reporter assay 
 
The Luciferase assay was performed using the Dual-Glo Luciferase Assay System (Promega). 
Luciferase and Renilla were used as co-reporters to measure gene expression. In order to generate 
luminescence Firefly luciferase requires luciferin, ATP, magnesium and molecular oxygen. Renilla 
luciferase requires coelenterazine and molecular oxygen.  
Cells were seeded into 24-well plates 24 hours prior to transfection, then, they were co-transfected 
with the reporter constructs, pRL-SV40, and with the expression plasmids. 48 hours post-
transfection, Dual-Glo Luciferase Reagent was added to each well in ratio 1:1 with the medium and 
cells were transferred to 96-well plate. After at least 10 minutes of incubation, the firefly 
luminescence was measured. Following the first measurement, an equal volume of Dual-Glo 
Stop&Glo Reagent was added and after 10 minutes incubation, the Renilla luminescence was 
measured.
52 
The results were expressed as Luciferase activity, normalized using the Renilla emission. 
 
 
8. Real time PCR 
 
Real time PCR or quantitative PCR (qPCR) was used to determine the amount of ORF26 and ATF4 
genes. β-actin housekeeping gene was used as internal control in order to normalize the results.  
qPCR using the TaqMan probes was performed using the 7300 ABI Prism (Applied Biosystems).  
The DNA or cDNA copy numbers were quantified by comparison with a 10-fold serial dilutions of 
known concentrations of pCG-ATF4 or pCR-ORF26 plasmids. The concentration of the standard 
DNA was assessed by spectrophotometer and plasmid copy numbers were calculated to prepare 
standard curves (10
7
 to 10
2
 copies).  
Amplifications were carried out in a 50 µL total volume containing 25 µL 2X TaqMan Universal 
PCR Master Mix (Applied Biosystems), 5 µL of primer and probes, and 20 µL template. The target 
genes were amplified using TaqMan FAM-labelled probe at the 5’-end and TAMRA quencher at 
the 3’-end. The β-actin housekeeping gene was simultaneously amplified using a 5’-VIC-labelled 
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probe. Primers and probes used are shown in Table 3. Concentrations of the primers and probes 
were 900 nM of each primer and 200 nM of each probe.  
The reaction conditions for all templates were 10 minutes at 95°C for enzyme activation, and 40 
cycles with 15 seconds at 95°C for DNA denaturation and 1 minute at 60°C for annealing and 
extension. Fluorescence data were collected in the primer elongation phase at 60°C.  
To normalise the data, the cycle threshold (Ct) values of the housekeeping gene were subtracted 
from the target gene Ct value of the sample. 
 
 
 
GENES 
 
 
PRIMERS & 
PROBES 
 
 
SEQUENCES 
 
ORF26 
 
H8-Forward  
H8-Reverse  
H8-Probe  
 
 
5'-CTCGAATCCAACGGATTTGAC-3’  
5'-TGCTGCAGAATAGCGTGCC-3'  
5’-(6Fam) CCATGGTCGTGCCGCAGCA (Tamra)-3’  
 
ATF4 
 
ATF4-Forward  
ATF4-Reverse  
ATF4-Probe  
 
 
5’-CCCCCCTAGTCCAGGAGACT-3’  
5’-CTGGGAGATGGCCAATTGG-3’  
5’-(6Fam) ATAAGCAGCCCCCCCAGACGG (Tamra)-3’  
 
β-actin 
 
β-ACT-Forward  
β-ACT-Reverse  
β-ACT-Probe  
 
 
5'-TCACCCACACTGTGCCCATCT-3'  
5'-GACTACCTCATGAAGATCCTCAC-3'  
5’-(Vic) ATGCCCTCCCCCATGCCATCCTGCGT (Tamra)-3’  
 
Table 3. Primer and probe sets used for real time PCR quantifications. 
 
 
 
9. Western blotting 
 
Cell samples (1-2*10
6
) were harvested and centrifuged 2 minutes at 8000 x g. Pellets were 
suspended in lysis buffer (6,7 M urea, 10 mM Tris-HCl pH 6.8, 5 mM DTT, 1% SDS, 10% 
glycerol, protease inhibitors cocktail) and debris was eliminated by centrifugation. 6X loading 
buffer was added to 20 µg cellular total lysated, and the mixture was subjected to 10% SDS-PAGE 
electrophoresis. Following electrophoresis, proteins were transferred in the Hibond-P PVDF-
membrane (Amersham) in an electroblotter (Biorad). After transfer, the membrane was probed with 
the rabbit anti-ATF4 antibody (SantaCruz Biotechnology) 1:200 diluted, 90 minutes at room 
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temperature. After three washes, the membrane was incubated with the anti-rabbit HRP conjugated 
antibody (SantaCruz Biotechnology) 1:1000 diluted for 90 minutes at room temperature. After three 
washes the antibody was revealed by luminol staining (SuperSignal West Pico Chemiluminescent 
Substrate, Pierce). ATF4 molecular weight is 38 kDa. 
 
 
10. ELISA 
 
For MCP-1 release analysis, supernatants from HHV-8 infected, mock-infected or transfected 
HUVECs were collected at different times after infection, cleared by centrifugation to eliminate cell 
debris, and stored at -80 °C. After thawing, samples were analyzed for the presence of MCP-1 using 
a specific quantitative ELISA kit (Biosource International, Camarillo, CA), following 
manufacturer’s instructions. Each sample was tested in triplicate. 
 
 
11. Immunofluorescence 
 
Antigen expression of HHV-8 was evaluated by immunofluorescence (IFA), performed on 5x10
4
 
infected cells fixed with cold methanol/acetone (50:50), and incubated with antibodies directed 
against lytic antigen (ORFK8.1) and nuclear antigen associated to latency (ORF73), as already 
described (Caselli et al., 2007). After primary antibody incubation, secondary antibodies (anti-
mouse IgG, fluorescein conjugated, Sigma) were added and slides were mounted for fluorescence 
observation using a Nikon Eclipse TE2000-S microscope. 
 
 
12.  HHV-8 infection 
 
HHV-8 inoculum was obtained from BC-3 cell line stimulated with TPA (20 ng/ml) for 72 h, and 
virions were purified by density centrifugation using Optiprep self-forming gradients (Sentinel, 
Milan, Italy), as previously described
56
. Cell-free purified virions were suspended in PBS 
containing 1% BSA, and stored at -80 °C until use. Virus stock was quantitated by real-time
 
PCR 
TaqMan assays (qPCR) as already described
41
, and contained 5x10
5
 copies of viral DNA/µl. Prior 
to use, virus stock was treated for 10 min at room temperature with DNase-I and RNase-A, to 
eliminate free viral nucleic acids potentially present in the preparation. Infective titers were 
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determined by counting the number of cells positive for the HHV-8 K8.1 protein by 
immunofluorescence at 36 h after infection, as previously described
41
. 
For in vitro infection experiments HUVEC, HMEC, 293 or Jurkat cells were seeded at optimal 
density 24 h before infection, and subsequently infected  as already described
41,56,59
. Briefly, 0.5 x 
10
6
 cells were washed once with PBS and infected with 10 µl of purified virus preparation (i.e. 
5x10
6
 copies of viral DNA, corresponding to a m.o.i. 10:1). After 3 h of absorption at 37°C, the 
viral inoculum was removed, cells were washed with PBS and incubated in complete medium for 
the designed times. Cell samples were harvested at specific time points for subsequent analyses. 
Control samples were uninfected or mock-infected with UV-inactivated HHV-8, obtained by 
exposing the purified inoculum under UV light (200 mJ per cm
2
) for 30 min
41
.  
 
 
13. Analysis of in vitro cord formation capability 
 
In vitro capillary-like structure formation assay was performed using an extracellular basement 
membrane extract (BME; Cultrex; Trevigen, Gaithersburg, MA), as described
41
. Uninfected, 
infected or transfected HUVECs suspended in EGM-2 medium were seeded on solidified BME 
(5x10
4
 cells per well) and incubated at 37 °C. Tube formation on BME was analyzed at different 
times after cell seeding by optical microscopy. 
 
 
14. Small interfering RNA (siRNA) studies 
 
For silencing studies, HUVECs plated at optimal density were transfected with 100 nM (1.35 
μg/ml) of siRNA targeting human ATF4 or of unrelated Negative Control siRNA (Ambion), using 
the RNAiFect technique (Qiagen) and following manufacturer’s instructions. Effective knockdown 
of ATF4 transcription was checked by  RT-qPCR, using the gene expression assay described above 
(Applied Biosystems). 
 
 
15. Statistical analyses 
 
Statistical significance of the results was evaluated by Student’s t test. 
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RESULTS 
 
1. HHV-8 infection increases ATF4 expression 
 
The effect of HHV-8 infection on ATF4 expression was studied in different human cell types, 
including human primary endothelial cells (HUVECs, as representative of natural targets of HHV-8 
in vivo), immortalized microdermal endothelial cells (HMEC), epithelial cells (293 cell line) and T 
lymphocytes (Jurkat cell line). As previously reported by us, HHV-8 supports a productive infection 
in all these cell types, followed by the establishment of latency at 5-10 days post infection 
(d.p.i.)
41,56,59,70
 .Efficiency of infection ranged between 15% (293 and Jurkat T cells) and 20% 
(HMEC and HUVEC), as measured by virus K8.1 antigen expression by immunofluorescence 
(IFA). Control samples were uninfected or mock-infected with UV-inactivated HHV-8. 
HHV-8 infected and control cells were analysed for ATF4 expression at 8, 24, 48 and 72 hours post 
infection (h.p.i.) by quantitative real time PCR after retrotranscription (RT-qPCR) and Western blot. 
The results (Fig. 1) showed that HHV-8 infection induces a substantial increase of ATF4 
transcription and translation, compared to levels detected in uninfected or mock infected cells. 
Transcriptional increase was present as early as 8 h.p.i. and peaked at 24 h.p.i., when levels of 
ATF4 mRNA were 10 times higher compared to controls. The increase persisted at 48 and 72 h.p.i., 
although slowly declining. ATF4 protein increased consistently and accumulated till 72 h.p.i., when 
protein amount was 6.9 fold compared to mock-infected samples. 
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A 
 
B 
            
 
 
 
 
 
 
 
 
 
Fig.1. HHV-8 infection increases ATF4 expression. (A) ATF4 mRNA was quantitated by RT-qPCR, using a template 
of cDNA derived from 200 ng of total RNA. (B) ATF4 protein production was analyzed by Western blot, performed on 
100 µg of total cell protein lysate.  
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 The increase of ATF4 following HHV-8 infection was observed with small variations in all the 
tested cell types (Table 1), indicating that ATF4 upregulation occurs as an early event in HHV-8 
infected cells, independently from the cell type and from the subsequent development of productive 
infection.  
 
  
Cell type ATF4 mRNA
a
 ATF4 protein
b
 
HUVEC 9.5±0.1 9.5±0.1 
HMEC 9.6±0.2 7.5±0.1 
293 epithelial cells 10.1±0.2 8.2±0.2 
Jurkat T cells  10.2±0.1 9.4±0.2 
 
Table 1. HHV-8 infection induces ATF4 expression in different cell types. 
a 
ATF4 transcriptional activation was 
measured by RT-qPCR at 24 h.p.i. 
b 
ATF4 protein accumulation was measured by western blot at 72 h.p.i. 
Results are expressed as fold increase compared to control levels (mean value of uninfected and mock infected cells), 
and represent the mean of triplicate samples in at least two different experiments. 
 
 
UV-irradiated HHV-8 did not induce any ATF4 increase, suggesting that the observed ATF4 
upregulation was not a consequence of mere virus binding to the cells, but it was dependent on the 
expression of early virus functions. We therefore studied the effect of HHV-8 ORF50, an immediate 
early function with a key role in activating viral replication, on the induction of ATF4. The same 
cell types were transfected with pCR-ORF50 plasmid, and ATF4 expression was analyzed by RT-
qPCR and Western blot at 8, 24, 48 and 72 hours post transfection (h.p.t.). Control cells were 
transfected with pCR-ORF57 or pCR empty vector. ORF50 expression induced a 4-fold increase of 
ATF4 mRNA and a 3-fold increase of ATF4 protein compared to controls (Fig. 2), suggesting that 
ORF50 is important for ATF4 induction in infected cells. Similar results were obtained in all the 
cell types tested (Table 2). 
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A 
 
B 
 
 
Fig. 2. HUVECs were transfected with pCR-ORF50, pCR-ORF57 or pCR empty vector (control), and collected at the 
indicated hours post transfection (h.p.t.). ATF4 mRNA was quantitated by RT-qPCR, using a template of cDNA 
derived from 200 ng of total RNA. ATF4 protein production was  analyzed by western blot, performed on 100 µg of 
total cell protein lysate. Results are expressed as the mean fold increase of triplicate samples in at least three different 
assays. Results of densitometric analysis of western blot were plotted and expressed as the mean ± SD of duplicate 
samples in three different experiments. 
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Cell type ATF4 mRNA
a
 ATF4 protein
b
 
HUVEC 4.2 ± 0.3 3.1 ± 0.2 
HMEC 4.5 ± 0.2 3.2 ± 0.5 
293 epithelial cells 4.1 ± 0.5 3.0 ± 0.1 
Jurkat T cells  4.0 ± 0.3 2.8 ± 0.2 
 
Table 2. ORF50 transfection mimics ATF4 induction by HHV-8 infection in different cell types. 
a 
ATF4 transcriptional 
activation was measured by RT-qPCR at 24 h.p.i. 
b 
ATF4 protein accumulation was measured by western blot at 72 
h.p.i. 
Results are expressed as fold increase ± SD observed in ORF50-transfected cells compared to control levels (mean 
value of non transfected and pCR-transfected cells), and represent the mean of triplicate samples in three different 
experiments. 
 
 
2. ATF4 increases HHV-8 replication 
 
Since HHV-8 infection upregulates ATF4 expression, we analyzed whether the increase of ATF4 
was beneficial for virus replication. The same cell types used for HHV-8 infection were transfected 
with a plasmid encoding the full length ATF4 gene (pCG-ATF4) or with the pCG empty vector 
(control), and subsequently infected with HHV-8. Virus replication and transcription were analyzed 
at 8, 24 and 48 h.p.i., by qPCR and RT-PCR performed on ORF50 (immediate early, IE) and 
ORF26 (late, L) virus genes. Results showed that virus replication was strongly increased in pCG-
ATF4 transfected cells compared to control pCG-transfected cells (Fig. 3). In particular, the amount 
of virus DNA increased 10 to 100 fold, depending on the cell type, being higher in HUVECs and 
Jurkat cells (100-fold) compared to 293 and HMEC cells (10 and 40-fold, respectively).  
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Fig. 3. ATF4 increases HHV-8 replication. HUVECs were transfected with pCG-ATF4 or pCG plasmid infected with 
HHV-8 (24 hours post-transfection, h.p.t.) and collected at the indicated hours post-infection (h.p.i.) to analyze virus 
replication. Virus genomes were quantitated by qPCR specific for the ORF26 gene, using 100 ng of total extracted 
DNA. The results represent the mean ± SD of triplicate samples in three different experiments. 
 
 
Also viral transcripts increased significantly, as shown by RT-qPCR results, with about 1 log 
increase of both IE (ORF50) and L (ORF26) mRNAs (Fig. 4).  
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Fig. 4. Virus transcription was analysed by real time qPCR specific for ORF26 mRNA, which was quantitated versus 
the internal control RNaseP, as described in Materials and Methods. 
 
 
 
The results were confirmed by the analysis of virus expression, performed by immunofluorescence 
on ORFK8.1 (lytic) and ORF73-LANA (latent) proteins. The number of antigen-expressing cells 
almost doubled in ATF4-transfected cells compared to control cells (Fig. 5). 
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Fig. 5. Virus antigen expression was analyzed by IFA using anti- ORFK8.1 and anti-LANA mAb. Results refer to 72 
h.p.i.. Pictures were taken with a Nikon Eclipse TE2000-S microscope equipped for fluorescence observation. Original 
magnification 4X.  
 
 
3. ATF4 does not activate HHV-8 promoters  
 
To characterize the effect of ATF4 upon HHV-8 replication, we studied its ability to transactivate 
HHV-8 promoters. HUVEC, 293 and Jurkat cells were cotransfected with plasmids encoding the 
luciferase (luc) gene under the transcriptional control of HHV-8 ORF50, ORF57 or T1.1 promoters 
(pGL-50pr, pGL-57pr, pGL-T1.1pr) and a plasmid encoding ATF-4 (pCG-ATF4) or pCG vector 
alone (control). A plasmid coding for ORF50 transactivator (pCR-50sp) was cotransfected as 
positive transactivation control
71
. As shown in Fig. 6 (A, B and C), ATF4 did not activate any of the 
tested HHV-8 promoters, neither directly or synergizing with ORF50, suggesting that ATF4 does 
not have a direct transcriptional effect on HHV-8 promoters. 
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Fig. 6. ATF4 does not activate HHV-8 promoters. The cells were transfected with reporter plasmids containing the luc 
gene cloned under the transcriptional control of HHV-8 ORF50 (A), ORF57 (B) or T1.1 (C) gene promoters, then 
luciferase activity was analyzed 30 h.p.t.. Results are expressed as folds activation compared to negative control 
(value=1) and represent the mean ± SD of triplicate samples in three different assays. 
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4. ATF4 activates the MCP-1 promoter and induces MCP-1 secretion 
 
We previously reported that NF-κB inhibitors affect only partially HHV-8 induced production of 
MCP-1 and its resulting capillary-like structure formation in HUVECs
41
, suggesting that another 
factor was involved in MCP-1 activation. We therefore tested the hypothesis of a direct role of 
ATF4 in inducing MCP-1 transcription.  
HUVECs were cotransfected with pCG-ATF4 or pCG plasmids, and with plasmids containing the 
reporter luc gene cloned downstream the MCP-1 promoter/enhancer regions: pGLM-PRM 
(containing the proximal promoter region of the MCP-1 gene), pGLM-ENH (containing both the 
proximal promoter and the distal enhancer regions), and pGLM-MA1, pGLM-MA2 and pGLM-
MA1A2, where one or both NF-κB binding sites (A1 and A2) in the enhancer region are mutated. 
As a positive control of NF-κB activation, 12 h.p.t. cells were treated with TPA. As expected, TPA 
treatment caused a significant transcriptional activation in cells transfected with the pGLM-ENH 
plasmid (5.1 fold), containing both MCP-1 promoter and enhancer, and deletion/mutation of κB 
sites resulted in the loss of TPA-induced activation (Fig. 7). Instead, ATF4 transfection resulted in 
an increase of luc expression independently from the presence of a functional MCP-1 enhancer 
region. Similar values were in fact observed in cells transfected with plasmids containing or lacking 
a functional MCP-1 enhancer region, suggesting that ATF4 activates directly the MCP-1 promoter, 
and that the κB sites in the enhancer region are not needed for ATF4 stimulation. Experiments 
performed in 293 cells gave similar results (not shown).  
 
 
 
Fig. 7. ATF4 activates MCP-1 promoter and induces production of MCP-1. HUVECs were cotransfected with pCG-
ATF4 or pCG (control) plasmids and  the indicated luc reporter plasmids: pGLM-PRM (containing the enhancer-less 
MCP-1 promoter), pGLM-ENH (containing the complete MCP-1 promoter-enhancer), and pGLM-MA1, pGLM-MA2 
and pGLM-MA1A2 (containing the complete MCP-1 promoter-enhancer region where one or both NF-κB sites are 
mutated). Positive control samples were treated with 100 ng/ml TPA at 12 h.p.t.. Luciferase activity was analyzed at 30 
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h.p.t. and is expressed as fold activation relative to the basal level of controls (value  = 1). Results represent the mean ± 
SD of triplicate samples in two different assays. 
 
 
ELISA analysis of the culture supernatant showed that ATF4 activation of MCP-1 promoter 
resulted in MCP-1 induction, as shown by the release of up to 1200 pg /ml of MCP-1 at 48 h.p.t. 
(Fig. 8). As expected, the amount of MCP-1 induced by ATF4 alone was lower than that induced by 
HHV-8 infection, due to the simultaneous involvement of NF-kB activation
41
 and this probably 
accounts for the residual activity that was not blocked by  NF-kB inhibitors. 
 
 
 
Fig. 8. HUVECs were transfected with pCG-ATF4 or pCG (control) or infected with HHV-8. MCP-1 release was 
analyzed by ELISA on culture supernatants collected at 24 or 48 h.p.i. or h.p.t.. Results are expressed as concentrations 
of chemokine in culture medium  (pg /ml) and represent the mean ± SD of duplicate samples in three different 
experiments. 
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5. ATF4 induces capillary-like structure formation in endothelial cells 
 
We investigated the ability of ATF4 to induce tube formation in HUVECs. Cells were transfected 
with pCG-ATF4 or pCG empty vector (negative control), or infected with HHV-8 (positive 
control), and then seeded on BME 24 h.p.t./h.p.i.. The formation of tubule-like structures was 
evaluated 24 hours later (Fig.9). As expected, HHV-8 infected HUVECs formed an extensive 
network of capillary-like structures, confirming our previous results
41
.  Interestingly, also ATF4-
transfected HUVECs showed a pro-angiogenic phenotype, although with lower efficiency 
compared to viral infection, suggesting that high levels of ATF4 can induce a proangiogenic 
behavior, even in the absence of viral infection. 
 
 
 
Fig. 9. ATF4 induces capillary-like formation in endothelial cells. HUVECs were transfected with pCG-ATF4 or pCG 
plasmids, or infected with HHV-8, and seeded on solidified RGF-BME (5x10
4
 cells/well/cm
2
) at 37°C and 5% CO2 in 
EBM (no serum or angiogenic factors). Tube formation was analyzed by optical microscopy at different times after cell 
seeding.  After 24 hours, cells were observed by optical microscopy (Nikon Eclipse TE2000-S microscope). Original 
magnification 4X.  
 
Pag. 57 
 
  
 
6. ATF4 silencing impairs HHV-8 replication and induction of proangiogenic properties 
 
To verify the role of ATF4 in HHV-8 biology, ATF4 expression  was silenced through transfection 
of small interfering RNA (siRNA) prior to HHV-8 infection. Control cells were transfected with 
scrambled unrelated siRNA. Effective knockdown of ATF4 transcription was checked by RT-
qPCR, and inhibition of ATF4 transcription was 80%  at 24 h.p.t. (Fig. 10). Silenced or non 
silenced cells were infected with HHV-8, and virus replication was analyzed at 24, 48, and 72 h.p.i. 
by qPCR (DNA) and RT-qPCR (RNA). As shown in Fig. 11, ATF4 silencing caused a significant 
impairment of HHV-8 replication, and the amount of viral DNA was approximately 70% less 
compared to non-silenced cells. Analysis of viral transcripts confirmed these results (not shown).  
 
 
 
 
Fig. 10. ATF4 silencing. Cells were untransfected (control) or transfected with scrambled unrelated siRNA (NC) or 
with anti-ATF4 siRNA (ATF4[-]). ATF4 transcription was evaluated by RT-qPCR 24 h.p.t.. Results are expressed as 
percentages relative to the control cells. 
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Fig. 11. ATF4 silencing impairs HHV-8 replication. Untransfected, NC-transfected and ATF4 siRNA-transfected cells 
were infected with HHV-8 at 24 h.p.t.. Cells samples were collected at the indicated h.p.i. for analysis of virus 
replication by qPCR (ORF26 gene). Results are expressed as the number of target molecules per 100 ng of  cellular 
DNA and represent the mean ± SD of triplicate samples in three different experiments. 
 
 
ATF4 silencing inhibited also the production of MCP-1 and the formation of HHV-8 induced 
tubule-like structures in HUVECs (Fig. 12).  MCP-1 production was 40% lower in ATF4-silenced 
cells than in control cells.  
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Fig. 12. ATF4 silencing inhibits virus-induced MCP-1 production in HUVECs. Cells were untransfected (control) or 
transfected with scrambled unrelated siRNA (NC) or with anti-ATF4 siRNA (ATF4[-]), and then infected with HHV-8 
at 24 h.p.t.. Cell culture supernatants were collected at the indicated h.p.i. for analysis of MCP-1 release by specific 
ELISA. Results are expressed as pg/ml of chemokine in culture medium, and represent the mean ± SD of duplicate 
samples in three different experiments. 
 
As shown in Fig. 13, control cells infected with HHV-8 showed clear proangiogenic behavior. 
Instead, the formation of tubule-like structures was impaired in ATF4-silenced cells, confirming 
that ATF-4 is a mediator of HHV-8 proangiogenic potential. The inhibition was evident at early 
times post-seeding, whereas at later times, HHV-8-infected cells almost completely regained their 
ability to form tube-like structures, likely due to the decline in siRNA activity and to the parallel 
virus-induced NF-kB activation (not shown). By contrast, the simultaneous inhibition of NF-kB (by 
treatment with 5 µM MG132)
41
 and ATF4 (by specific siRNA) completely abolished the tube 
formation capability of HUVECs, but this was accompanied by a high level of cell mortality (not 
shown). 
 
 
0
1000
2000
3000
4000
5000
6000
7000
24 h 48 h
M
C
P
-1
 (
p
g
/m
l)
 
Time (h.p.i.) 
MCP-1 ELISA 
HHV8/C
HHV8/NC
HHV8/ATF4(-)
 
Pag. 60 
 
  
 
 
 
 
Fig. 13. ATF4 silencing inhibits virus-induced tubule-like structures formation in HUVECs. Cells were untransfected 
(control) or transfected with scrambled unrelated siRNA (NC) or with anti-ATF4 siRNA (ATF4[-]), and then infected 
with HHV-8 at 24 h.p.t.. Control untransfected, NC-transfected and ATF4 siRNA-transfected cells were not infected 
(N.I.) or infected with HHV-8 at 24 h.p.t.. Aftrer 24 h.p.i., cells were plated on RGF-BME (5x10
4
 cells/well/cm
2
) at 
37°C and 5% CO2 in EBM (no serum or angiogenic factors) and formation of tubule-like structures was evaluated 6 h 
post-seeding by optical microscopy (Nikon Eclipse TE2000-S microscope). Original magnification 4X. The results 
shown are representative of three different experiments.  
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DISCUSSION 
 
Kaposi’ Sarcoma is a vascular neoplasia characterized by the proliferation of neovascular 
formations and proliferating spindle cells, originating from endothelial cells. HHV-8 is essential 
for the development of all forms of KS, and its genome is detected in almost all neoplastic cells. 
Our previous results showed that the proangiogenic potential of HUVEC cells associated to 
HHV-8 infection is strictly dependent upon MCP-1
41
. In fact we described that HHV-8, 
consequently to a robust and sustained activation of cellular NF-κB factor, upregulates the 
expression of MCP-1. Interestingly, inhibition of MCP-1 activity by specific antibody abolished 
completely HUVEC tube formation, but inhibition of NF-κB resulted only in a reduction of 
MCP-1 levels and proangiogenic cell behavior. In our search for other factors involved in HHV-
8 triggering of MCP-1 production and angiogenesis, we focused on ATF4 as a potential 
candidate for the residual NF-κB-independent MCP-1 production. In fact, ATF4 is an essential 
mediator of MCP-1 expression in human endothelial
60
. In addition, ATF4 is overexpressed in 
tumours compared to normal tissues
61,53
, is related to hypoxia tolerance, tumour progression, 
VEGF expression and angiogenesis
62-64
. Therefore, we analyzed whether HHV-8 infection 
induces ATF4 expression in different cell types. Our results indicate that HHV-8 acute infection 
increases ATF4 expression, both at the transcriptional and translational levels, possibly due to 
the activation of the integrated stress response following virus entry and onset of replication. 
Although this notion is new for HHV-8, it has already been described for other viruses
65-68
, 
including another human herpesvirus,  HCMV. In general, viral infections trigger cellular stress 
responses, potentially resulting in attenuation of viral replication. In the case of HCMV, the virus 
induces the UPR but regulates its signal transduction pathway in order to eliminate deleterious 
effects while maintaining potentially beneficial ones deriving from activation of ATF4
69
. 
In this study we found a similar situation for HHV-8. Virus infection activates ATF4, which in 
turn enhances viral replication. This effect was observed in different cell types, suggesting that 
the induction of ATF4 is independent from the ability to develop a full productive infection. 
Transfection of the major viral transactivator, ORF50, reproduced in part the induction of ATF4 . 
Interestingly, it was previously reported that expression of HHV-8 latency-associated nuclear 
antigen (LANA) inhibits the transcriptional activation activity of ATF4
55
, confirming that ATF4 
induction is specifically associated to the early steps of acute HHV-8 infection, and supporting 
the hypothesis that ATF4 is an important requisite for viral replication. However, expression of 
ATF4 does not reactivate latent HHV-8,  and has no direct activating effect on the tested HHV-8 
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promoters, suggesting an indirect action on viral replication, possibly mediated by additional cell 
factors. 
Furthermore,  we show that viral induction of ATF4 might be responsible for the residual quote 
NF-kB independent of MCP-1 production. In fact, ATF4 transfection activates the MCP-1 
promoter in the region lacking NF-κB binding sites, it induces production and release of MCP-1, 
and overexpression of ATF4 promotes proangiogenic activity in endothelial cells. In addition, 
silencing of ATF4 results in a significant impairment of HHV-8 replication and in a partial 
inhibition of HHV-8 induced tubule-like structure formation in HUVECs.  
Our results show that the distinctive HHV-8 proangiogenic ability, strictly dependent on MCP-1, 
is the result of at least two converging pathways, one supported by NF-κB41 and one mediated by 
ATF4.  ATF4 is induced by HHV-8 acute infection, possibly by the expression of viral ORF50. 
Activation of ATF4 promotes HHV-8 replication and allows a full induction of virus-induced 
proangiogenic properties. Since these in vitro features mimic early stage tumorigenesis, we 
propose that ATF4 induction by HHV-8 can contribute to KS tumor development. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pag. 63 
 
  
MEETINGS and PUBLICATION LISTS 
 
Meetings: 
 
17th – 19th October 2010 
38° SIM – Riccione 
Abstract: Interazioni molecolari tra Herpes virus umano di tipo 8 (HHV-8) e fattore trascrizionale 
cellulare ATF4.  
Grigolato J., Benedetti S., Cassai E.,  Di Luca D., e Caselli E. 
 
17th – 19th October 2010 
38° SIM – Riccione 
Abstract: Presenza di HHV-6 in campioni tiroidei di pazienti con malattie autoimmuni della tiroide.  
Benedetti S., Di Luca D., Zatelli M.C., Degli Uberti E.C., Grigolato J., Cassai E.  e Caselli E. 
 
26th - 29th November 2007 
49° Congresso Nazionale Società  Italiana di Cancerologia - Pordenone  
Abstract: Infection by Human Herpesvirus-8 and upregulation of transcription factor  ATF4.  
Caselli E., Gentili V., Grigolato J, Ngakeu A., Cassai E., Di Luca D. 
 
30th September – 3rd October 2007 
35° Congresso Nazionale della Società Italiana di Microbiologia – Catania 
Abstract: L’Herpesvirus umano di tipo 8 (HHV-8) incrementa il fattore cellulare trascrizionale 
ATF4.  
Caselli E.; Gentili V.; Grigolato J.; Ngankeu A.; Di Luca D.. 
 
Papers published in peer-reviewed international journals: 
 
Caselli E, Benedetti S, Grigolato J, Caruso A, Di Luca D (2012). Activating Transcription Factor 4 
(ATF4) is upregulated by human herpesvirus 8 infection, increases virus replication and promotes 
proangiogenic properties. Arch Virol, 157: 63-74.  
 
Caselli E, Benedetti S, Gentili V, Grigolato J, Di Luca D (2012).  Activating Transcription Factor 4 
(ATF4) promotes HIV-1 activation. AIDS Res Hum Retroviruses, 28: 907-912. 
 
Pag. 64 
 
  
REFERENCES 
 
 
1. Roizman B., Sears A. (1998) - Herpes simplex viruses and their replication. In: Virology 
(vol.2) - III Edition. Fields BN., Knipe DM. Howley PM. (eds.) Lippincot-Raven 
Publishers, Philadelphia-New York, pp.2231- 2342. 
2. Furlong D, Swift H, Roizman B: Arrangement of herpes virus deoxyribonucleic acid in 
the core. Journal of Virology, 1972. 10 (5): 1071-1074. 
3. McCombs RM, Brunschwig JP, Mirkovic R, Benyesh-Melnick M: Electron microscopic 
characterization of a herpeslike virus isolated from three shrews. Virology, 1971. 45 (3): 
816-820. 
4. Deiss LP, Chou J, Frenkel N: Functional domains within the a sequence involved in the 
cleavage-packaging of the herpes simplex virus DNA. Journal of Virology, 1986. (3): 
605-618. 
5. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS. 
Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. 
Science, 1994. 266 (5192): 1865-1869. 
6. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM: Kaposi's sarcoma-associated 
herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. The 
New England journal of medicine, 1995. 332 (18): 1186-1191. 
7. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, d'Agay MF, 
Clauvel JP, Raphael M, Degos L, et al. Kaposi's sarcoma-associated herpesvirus-like 
DNA sequences in multicentric Castleman's disease. Blood, 1995. 86 (4): 1276-1280. 
8. Antman K, Chang Y. Kaposi's sarcoma. The New England journal of medicine, 2000. 
342 (14): 1027-1038. 
9. Luppi M, Barozzi P, Santagostino G, Trovato R, Schulz TF, Marasca R, Bottalico D, 
Bignardi L, Torelli G. Molecular evidence of organ-related transmission of Kaposi 
sarcoma-associated herpesvirus or human herpesvirus-8 in transplant patients. Blood, 
2000. 96 (9): 3279-3281. 
10. Wu L, Lo P, Yu X, Stoops JK, Forghani B, Zhou ZH: Three-dimensional of the human 
herpesvirus 8 capsid. Journal of Virology, 2000. 74 (20): 9646-9654. 
11. Renne R, Lagunoff M, Zhong W, Ganem D: The size and conformation of Kaposi's 
sarcoma associated herpesvirus (human herpesvirus 8) DNA in infected cells and virions. 
Journal of Virology, 1996. 70 (11): 8151-8154. 
 
Pag. 65 
 
  
12. Moore PS, Gao SJ, Dominguez G, Cesarman E, Lungu O, Knowles DM, Garber R, 
Pellett PE, McGeoch DJ, Chang Y: Primary characterization of a herpesvirus agent 
associated with Kaposi's sarcoma. Journal of Virology, 1996. 70 (1): 549-558. 
13. JP, Peruzzi D, Edelman IS, Chang Y, et al.: Nucleotide sequence of the Kaposi sarcoma-
associated herpesvirus (HHV-8). PNAS  USA, 1996. 93 (25): 14862-14867. 
14. Arvanitakis L, Geras-Raaka E, Varma A, Gershengorn MC, Cesarman E: Human 
herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to 
cell proliferation. Nature, 1997. 385 (6614): 347-350. 
15. Coscoy L, Ganem D: Kaposi's sarcoma-associated herpes virus encodes two proteins that 
block cell surface display of MHC class I chains by enhancing their endocytosis. PNAS 
USA, 2000. 97 (14): 8051-8056. 
16. Birkman A, Mahr K, Ensser A, Yaguboglu S, Titgemeyer F, Fleckenstein B, Neipel F: 
Cell surface heparan sulfate is a receptor for human herpesvirus 8 and interacts with 
envelope glycoprotein K8.1. Journal of  Virology, 2001. 75 (23): 11583-11593. 
17. Decker LL, Shankar P, Khan G, Freeman RB, Dezube BJ, Lieberman J, et al. The Kaposi 
sarcoma-associated herpesvirus (KSHV) is present as an intact latent genome in KS 
tissue but replicates in the peripheral blood mononuclear cells of KS patients. The 
Journal of experimental medicine, 1996.184: 283–288. 
18. Ballestas ME, Chatis PA, Kaye KM. Efficient persistence of extrachromosomal KSHV 
DNA mediated by latency-associated nuclear antigen. Science, 1999. 284: 641–644. 
19. Lu F, Day L, Gao SJ, Lieberman PM. Acetylation of the latency-associated nuclear 
antigen regulates repression of Kaposi’s sarcoma-associated herpesvirus lytic 
transcription. Journal of  Virology, 2006. 80: 5273–5282. 
20. Zhu FX, Cusano T, Yuan Y. Identification of the immediate early transcripts of Kaposi’s 
sarcoma-associated herpesvirus. Journal of Virology, 1999. 73 (7): 5556-5567. 
21. Lukac DM, Kirshner JR, and Ganem D. Transcriptional activation by the product of the 
open reading frame 50 of Kaposi’s-associated herpesvirus is required for lytic viral 
reactivation in B cells. Journal of Virology, 1999. 73: 9348–9361. 
22. Lukac DM, Garibyan L, Kirshner JR, Palmeri D, Ganem D. DNA binding by Kaposi’s 
Sarcoma-associated herpesvirus lytic switch protein is necessary for transcriptional 
activation of two viral delayed early promoters. Journal of Virology, 2001. 75 (15): 
6786–6799. 
23. Chang PJ, Shedd D, Gradoville L, Cho MS, Chen LW, Chang J, Miller G. Open reading 
frame 50 protein of Kaposi’s sarcoma-associated herpesvirus directly activates the viral 
 
Pag. 66 
 
  
PAN and K12 genes by binding to related response elements. Journal of Virology, 2002. 
76 (7): 3168-3178. 
24. Sakakibara S, Ueda K, Chen J, Okuno T, Yamanishi K. Octamer-binding sequence is a 
key element for the autoregulation of Kaposi’s sarcoma-associated herpesvirus 
ORF50/Lyta gene expression. Journal of Virology, 2001. 75: 6894-6900. 
25. Caselli E, Menegazzi P, Bracci A, Galvan M, Cassai E, Di Luca D. Human herpesvirus-8 
(Kaposi's sarcoma associated herpesvirus) ORF 50 interacts synergistically with the tat 
gene product in transactivating the human immunodeficiency virus type 1 LTR. Journal 
of General Virology, 2001. 82 (8): 1965- 1970. 
26. Caselli E, Galvan M, Santoni F, Rotola A, Caruso A, Cassai E, Di Luca D. Human 
herpesvirus-8 (Kaposi's sarcoma-associated virus) ORF50 increases in vitro cell 
susceptibility to human immunodeficiency virus type 1 infection. Journal of General 
Virology, 2003. 84 (5): 1123-1131. 
27. Kirshner JR, Lukac DM, Chang J, Ganem D. Kaposi's sarcoma - associated Herpesvirus 
ORF57 encodes a posttrascriptional regulator with multiple distinct activities. Journal of 
Virology, 2000. 74 (8): 3586-3597. 
28. Pauk J, Huang ML, Brodie SJ, Wald A, Koelle DM, Schacker T, Celum C, Selke S, 
Corey L: Mucosal shedding of human herpesvirus 8 in men. The New England journal of 
medicine, 2000. 343 (19): 1369-1377. 
29. Lacoste V, de la Fuente C, Kashanchi F, Pumfery A. Kaposi’s sarcoma-associated 
herpesvirus immediate early gene activity. Frontiers in Bioscience, 2004. 9: 2245–2272. 
30. Damania B. DNA tumor viruses and human cancer. Trends Microbiology, 2007. 15: 38–
44. 
31. Laman H, Boshoff C. Is KSHV lytic growth induced by a methylation-sensitive switch? 
Trends Microbiology, 2001. 9: 464–466. 
32. Kaposi M: Idiopathic multiple pigmented sarcoma of the skin. Archiv fur Dermatologie 
und Syphilis, 1872. 4: 265-273. 
33. Ensoli B, Sgadari C, Barillari G, Sirianni MC, Sturzl M, Monini P. Biology of Kaposi’s 
sarcoma. European Journal of Cancer, 2001. 37: 1251-1269. 
34. Tappero JW, Conant MA, Wolfe SF, Berger TG: Kaposi's sarcoma. Epidemiology, 
pathogenesis, histology, clinical spectrum, staging criteria and therapy. Journal of the 
American Academy of Dermatology, 1993. 28 (3): 371-395. 
35. Goedert JJ: The epidemiology of acquired immunodeficiency syndrome malignancies. 
Seminars in Oncology, 2000. 27 (4): 390-401. 
 
Pag. 67 
 
  
36. Wabinga HR, Parkin DM, Wabwire-Mangen F, Mugerwa JW: Cancer in Kampala, 
Uganda, in 1989–91: changes in incidence in the era of AIDS. International Journal of 
Cancer, 1993. 54 (1): 26-36. 
37. Dourmishev LA, Dourmishev AL, Palmeri D, Schwartz RA, Lukac DM: Molecular 
genetics of Kaposi's sarcoma-associated herpes virus human herpesvirus-8) epidemiology 
and pathogenesis. Microbiology & Molecular Biology Reviews, 2003. 67 (2): 175-212.  
38. Hengge UR, Ruzicka T, Tyring SK, Stuschke M, Roggendorf M, Schwartz RA, Seeber S: 
Update on Kaposi's sarcoma and other HHV-8 associated diseases Part 1: epidemiology, 
environmental predispositions, clinical manifestations, and therapy. The Lancet Infectious 
Diseases, 2002. 2 (5): 281-292. 
39. Katano H, Sato Y, Kurata T, Mori S, Sata T: Expression and localization of human 
herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and 
multicentric Castleman's disease. Virology, 2000. 269 (2): 335-344. 
40. Renne R, Zhong W, Herndier B, McGrath M, Abbay N, Kedes D, Ganem D. Lytic 
growth of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) in culture. 
Nature Medicine 1996. 2 (3): 342-346. 
41. Caselli E, Fiorentini S, Amici C, Di Luca D, Caruso A, Santoro MG. Human herpesvirus 
8 acute infection of endothelial cells induces monocyte chemoattractant protein 1-
dependent capillary-like structure formation: role of the IKK/NF-kB pathway. Blood, 
2007. 109 (7): 2718-2726. 
42. Hai T, Curran T. Cross-family dimerization of transcription factors Fos/Jun and 
ATF/CREB alters DNA binding specificity. PNAS USA, 1991. 88: 3720-3724. 
43. Harding HP, Zhang Y, Bertolotti A, Zeng H, Ron D. PERK is essential for translation 
regulation and cell survival during unfolded protein response. Molecular Cell, 2000. 5 
(5): 897-904. 
44. Schoch S, Cibelli G, Magin A, Steinmuller L, Thiel G. Modular structure of cAMP 
response element binding protein 2 (CREB2). Neurochemistry International, 2001. 38: 
601-608. 
45. Chevray PM, Nathans D. Protein interaction cloning in yeast: identification of 
mammalian proteins that react with the leucine zipper of Jun. PNAS USA, 1992. 89: 
5789-5793. 
46. Vallejo M, Ron D, Miller CP, Habener JF. C/ATF, a member of the activating 
transcription factor family of DNA-binding proteins, dimerizes with CAAT/enhancer-
binding proteins and directs their binding to cAMP response elements. PNAS USA, 1993. 
 
Pag. 68 
 
  
90: 4679-4683. 
47. Lassot I, Estrabaud E, Emiliani S, Benkirane M, Benarous R, Margottin-Goguet F. p300 
modulates ATF4 stability and transcriptional activity independently of its 
acetyltransferase domain. Journal of  Biological Chemistry, 2005. 280: 41537-41545. 
48. De Angelis R, Iezzi S, Bruno T, Corbi N, Di Padova M, Floridi A. Functional interaction 
of the subunit 3 of RNA polymerase II (RPB3) with transcription factor 4 (ATF4). FEBS 
Letters, 2003. 547: 15-19. 
49. Kawai T, Matsumoto M, Takeda K, Sanjo H, Akira S. ZIP kinase, a novel 
serine/threonine kinase which mediates apoptosis. Molecular and Cellular Biology, 1998. 
18: 1642-1651. 
50. Reddy TR, Tang H, Li X, Wong-Staal F. Functional interaction of the HTLV-1 
transactivator Tax with activating transcription factor-4 (ATF4). Oncogene, 1997. 14: 
2785-2792. 
51. Hai T, Hartman MG. The molecular biology and nomenclature of the activating 
transcription factor/cAMP responsive element binding family of transcription factor: 
activating transcription factor proteins and homeostasis. Gene, 2001. 273: 1-11. 
52. Harding HP, Zhang Y, Zeng H, Novoa I, Lu PD, Calfon M, Sadri N, Yun C, Popko B, 
Paules R, Stojdl DF, Bell JC, Hettmann T, Leiden JM, Ron D. An integrated stress 
response regulates amino acid metabolism and resistance to oxidative stress. Molecular 
Cell, 2003. 11 (3): 619-633. 
53. Bi M, NaczKi C, Koritzinsky M, Fels D, Blais J Hu N. ER stress-regulated translation 
increases tolerance to extreme hypoxia and promotes tumour growth. The Embo Journal, 
2005. 24: 3470-3481. 
54. Isler JA, Skalet AH and Alwine JC. Human Cytomegalovirus Infection Activates and 
Regulates the Unfolded Protein Response. Journal of Virology, 2004. 79 (11): 6890-
6899. 
55. Lim C, Sohn H, Gwack Y, Choe J. Latency associated nuclear antigen of Kaposi’s 
sarcoma-associated herpesvirus (human herpesvirus-8) binds ATF4/CREB2 and inhibits 
its transcriptional activation activity. Journal of General Virology, 2000. 81, 2645-2652. 
56. Caselli E, Galvan M, Cassai E, Caruso A, Sighinolfi L, Di Luca D. Human herpesvirus 8 
enhances human immunodeficiency virus replication in acutely infected cells and induces 
reactivation in latency infected cells. Blood, 2005. 106 (8), 2790-2797. 
     57. Conaldi PG, Serra C, Mossa A, Falcone V, Basolo F, Camussi G, Dolei A, Toniolo A. 
 Persistent infection of human vascular endothelial cells by group B coxsackieviruses. J 
 
Pag. 69 
 
  
 Infect Dis, 1997. 175 (3), 693-696. 
     58. Arvanitakis L, Mesri EA, Nador RG, Said JW, Asch AS, Knowles DM, Cesarman E. 
 Establishment and characterization of a primary effusion (body cavity-based)  lymphoma 
 cell line (BC-3) harboring kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in  the 
 absence of Epstein-Barr virus. Blood, 1996. 88(7), 2648-2654. 
     59. Fonsato V, Buttiglieri S, Deregibus MC, Bussolati B, Caselli E, Di Luca D, Camussi G. 
 PAX2 expression by HHV-8 infected endothelial cells induced a proangiogenic and 
 proinvasive phenotype. Blood, 2008. 111 (5), 2806-2815. 
    60. Gargalovic PS, Gharavi NM, Clark MJ, Pagnon J, Yang WP, He A, Truong A, Baruch-Oren 
T, Berliner JA, Kirchgessner TG, Lusis AJ. The unfolded protein response is an important 
regulator of inflammatory genes in endothelial cells. Arterioscler Thromb Vasc Biol, 2006. 
26(11), 2490-2496. 
    61. Ameri K, Lewis CE, Raida M, Sowter H, Hai T, Harris AL. Anoxic induction of ATF-4 
through HIF-1-independent pathways of protein stabilization in  human cancer cells. Blood, 
2004. 103(5), 1876-1882. 
    62. Chakraborty G, Jain S, Kundu GC. Osteopontin promotes vascular endothelial growth factor-
dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. 
Cancer Res, 2008. 68(1), 152-161. 
    63. Fels D, Koumenis C. The PERK/eIF2alpha/ATF4 module of the UPR in hypoxia resistance 
and tumor growth. Cancer Biol Ther, 2006. 5(7), 723-728. 
    64. Pereira ER, Liao N, Neale GA, Hendershot LM. Transcriptional and post-transcriptional 
regulation of proangiogenic factors by the unfolded protein response. PLoS One, 2010. 5(9). 
    65. Granberg F, Svensson C, Pettersson U, Zhao H. Adenovirus-induced alterations in host cell 
gene expression prior to the onset of viral gene expression. Virology, 2006. 353(1), 1-5. 
    66. Jordan R., Wang L., Graczyk TM, Block TM, Romano PR. Replication of a cytopathic strain 
of bovine viral diarrhea virus activates PERK and induces endoplasmic reticulum stress-
mediated apoptosis of MDBK cells. J Virol, 2002. 76(19), 9588-9599. 
    67. Su HL, Liao CL, Lin YL. Japanese encephalitis virus infection initiates endoplasmic 
reticulum stress and an unfolded protein response. J Virol, 2002. 76(9), 4162-4171. 
    68. Tardif KD, Mori K, Siddiqui A. Hepatitis C virus subgenomic replicons induce endoplasmic 
reticulum stress activating an intracellular signaling pathway. J Virol, 2002. 76(15), 7453-
7459. 
    69. Isler JA, Skalet AH, Alwine JC. Human cytomegalovirus infection activates and regulates the 
unfolded protein response. J Virol, 2005. 79(11), 6890-6899. 
 
Pag. 70 
 
  
    70.  Caselli E, Galvan M, Santoni F, Alvarez S, De Lera, AR, Ivanova D, Gronemeyer  H, Caruso 
 A, Guidoboni M, Cassai E, Dolcetti R, Di Luca D. Retinoic acid  analogues inhibit human 
 herpesvirus 8 replication. Antivir Ther, 2008. 13, 199-209. 
    71.  Santoni F, Lindner I, Caselli E, Goltz M, Di Luca D, Ehlers B. Molecular  interaction 
 between porcine and human gammaherpesviruses:implication for xenografts? 
 Xenotransplantation, 2006. 13, 308-317. 
 
